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ABSTRACT 
Structural studies of the yeast transcription termination complex Nrd1-Nab3-Sen1 
Yinglu Zhang 
 
The Nrd1-Nab3-Sen1 (NNS) complex carries out the RNA polymerase II (Pol II) 
transcription termination of non-coding RNAs (ncRNAs) in yeast, although the detailed 
interactions among its subunits remain obscure. In this dissertation, we have identified three 
sequence motifs in Sen1 that mediate direct interactions with the Pol II CTD interaction domain 
(CID) of Nrd1, determined the crystal structures of these Nrd1 interaction motifs (NIMs) bound to 
the CID, which elucidated the molecular basis for their recognition by Nrd1 CID, and characterized 
the interactions in vitro and in yeast. Although the Sen1 NIMs are not essential for supporting 
viability from the in vivo studies, termination defects were observed from NIM deletions in a 
reporter assay. In addition, the conservation of Sen1 NIMs suggests these interactions are very 
likely to promote NNS function.  
This dissertation also describes the structural studies of the flowering time control protein 
FPA in plants, which regulates the alternative 3’-end processing of the FLOWERING LOCUS C 
(FLC) antisense RNA. FPA belongs to the split ends (SPEN) family of proteins, which contain N-
terminal RNA recognition motifs (RRMs) and a SPEN paralog and ortholog C-terminal (SPOC) 
domain. The SPOC domain is highly conserved among FPA homologs in plants, but the 
conservation with the domain in other SPEN proteins is much lower. We have determined the 
crystal structure of Arabidopsis thaliana FPA SPOC domain at 2.7 Å resolution. Structural and 
sequence analyses identify a surface patch that is conserved among plant FPA homologs. 
Mutations of two residues in this surface patch did not disrupt FPA functions, suggesting that 
 
either the SPOC domain is not required for the role of FPA in regulating RNA 3’-end formation 
or the functions of the FPA SPOC domain cannot be disrupted by this combination of mutations. 
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This dissertation summarizes the projects I have worked on over the course of my Ph.D. 
study. The majority of my work was studying the Nrd1-Nab3-Sen1 complex, which is involved in 
RNA polymerase II transcription termination and the coupled RNA processing and degradation in 
yeast. I also describe my work on the structural studies of a flowering time control protein FPA, a 
methyltransferase SETD2 modulated by oncogenic histone mutations, a 5’-3’ exoribonuclease 




Transcription termination of non-coding RNAs in yeast 
 
1.1 Overview of eukaryotic transcription 
 Transcription is the starting point of gene expression in eukaryotic cells, which is carried 
out by three different RNA polymerases, RNA polymerase I (Pol I), RNA polymerase II (Pol II), 
and RNA polymerase III (Pol III). Pol I produces ribosomal RNAs (rRNAs), and Pol III 
synthesizes transfer RNAs (tRNAs) and 5S rRNA, which in total make up around 90% of the RNA 
produced (1). Pol II synthesizes messenger RNAs (mRNAs) and some non-coding RNAs 
(ncRNAs), such as microRNAs, small nuclear RNAs (snRNAs), small nucleolar RNAs 
(snoRNAs), cryptic unstable transcripts (CUTs), and stable unannotated transcripts (SUTs) (2-4). 
Although the RNAs transcribed by Pol II usually have low expression levels and high turnover 
rates, which constitute only 10% of the total cellular RNA population, they are functionally 
important in various biological processes (1). mRNAs are transcribed from protein-coding genes, 
which conveys the genetic information for protein synthesis. Although ncRNAs are not encoded 
for protein production, they have regulatory roles in processes of gene expression, such as 
transcription, splicing, mRNA turnover, gene silencing, and translation (5). 
 Pol II transcription involves three stages: initiation, elongation, and termination (Figure 1-
1). During initiation, Pol II is recruited to a gene promoter on the DNA and assembled with the 
transcription factors TFIIB, TFIIA, and TFIID, which contains the TATA box-binding protein 
(TBP) that specifically binds to the TATA-box with a consensus sequence of TATAWAWR 
(W=A/T, R=A/G) (6). Transcription factors TFIIF, TFIIE, and TFIIH were then added sequentially 
to form the pre-initiation complex (PIC) and initiate RNA synthesis (7, 8). When the synthesized 
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RNA reaches around 8-9 nucleotides, the RNA-DNA hybrid stimulates the escape of Pol II from 
the promoter to commence early elongation (7). 
 During the early elongation stage, Pol II usually pauses at the promoter-proximal region, 
30–60 nucleotides downstream of the transcription start site (9, 10). The paused Pol II is stabilized 
by the transcription factors, negative elongation factor (NELF), and DRB-sensitivity-inducing 
factor (DSIF), which is a heterodimer of SPT4 and SPT5 (9, 10). This step acts as a checkpoint of 
the 5’-end capping of the transcript for RNA stability and the modifications of Pol II for regulatory 
control (11). The productive elongation is triggered when the positive transcription elongation 
factor-b (P-TEFb) complex, which consists of cyclin T1 and cyclin-dependent kinase 9 (CDK9), 
is recruited and releases Pol II from pausing by phosphorylation of NELF, DSIF, and Pol II (12, 
13). The stable Pol II complex is able to continue transcribing from the DNA template until 
transcription termination is triggered. 
Transcription termination is carried out with the facilitation of different transcription 
factors, which collapses the transcription bubble and releases the Pol II and nascent RNA from the 
template DNA (4). The process is usually coupled with the 3’-end processing of the nascent RNA 
transcripts, and also induces the degradation of aberrant or unwanted RNAs (14). In human, 
mRNAs and ncRNAs undergo two distinct transcription termination pathways. The poly(A)-
dependent termination for mRNAs is coupled with 3’-end cleavage and polyadenylation of the 
nascent transcripts, which involves the cleavage and polyadenylation specificity factor (CPSF) and 
the cleavage stimulatory factor (CstF) (15), and the 3’-end processing is initiated when the poly(A) 
signal (PAS), AAUAAA, of the transcripts is recognized by CPSF (4). The Integrator termination 
pathway targets non-coding RNAs, such as U-rich small nuclear RNA (UsnRNA) and enhancer 
RNAs (eRNAs), and involves a protein complex of 14 subunits, although the detailed functions 
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for most of the subunits still remain obscure (16, 17). Different transcription termination 
mechanisms for mRNAs and ncRNAs are also observed in S. cerevisiae, which will be discussed 
in more detail here. The transcription termination pathway for mRNAs is PAS-mediated, which 
involves the cleavage and polyadenylation factor (CPF) and the cleavage factor I A and B (CFI), 
which are homologs of the human CPSF and CstF (18). For comparison, the transcription 
termination pathway for most non-coding RNAs (ncRNAs) is Nrd1-Nab3-Sen1 (NNS)-mediated, 
which involves the Nrd1-Nab3-Sen1 complex and will be discussed in detail (19, 20).  
In conclusion, the protein factors involved in the three stages of eukaryotic transcription 
are mostly identified, but the detailed function mechanisms of many still remain unknown. 
Therefore, structural, biochemical, and functional insights into these proteins will greatly 
contribute to our understanding of the pathways involved in eukaryotic transcription. 
 
 
Figure 1-1. Three stages of RNA polymerase II (Pol II) transcription (adapted from (4)). Pol II 
transcription involves three stages: initiation, elongation, and termination. Initiation: Pol II (shown as green) 
is recruited to a gene promoter by transcription factors, the DNA is melted to expose the template strand, 
and the first few nucleotides of RNA are synthesized. Elongation: a full-length RNA–DNA hybrid is formed 
and Pol II proceeds to extend the transcript. Termination: Pol II ceases RNA synthesis and becomes 
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termination-prone (shown as yellow), and both Pol II and the nascent RNA are released from the template. 
Protein factors involved in elongation, RNA processing and termination are shown as yellow, blue and 
orange ovals, respectively. 
 
1.2 Transcription regulation by the RNA polymerase II CTD 
All three stages of eukaryotic transcription, initiation, elongation, and termination, are 
under extensive regulations to ensure precise orchestration of the protein factors involved. The 
regulation relies mainly on the extended unstructured carboxy-terminal domain (CTD) of the Rpb1 
subunit of Pol II complex, which acts as a scaffold for recruitment of various transcription factors 
(21). The CTD consists of heptapeptide repeats with the consensus sequence YSPTSPS, and the 
number of repeats varies in different eukaryotic organisms, such as 5 in P. yoelii, 26 in S. cerevisiae, 
and 52 in humans (21, 22). Genetic studies showed that ten repeats are needed for growing wild-
type yeast on rich media, and 13 repeats are required to overcome stress conditions such as 
temperature sensitivity, cold sensitivity, and auxotrophic phenotypes (23, 24). Furthermore, 
although not crucial, a full-length CTD is preferred and actively maintained by the cell (21). 
During different stages of transcription, the CTD is subjected to phosphorylation, proline 
isomerization, and O-GlcNAcylation at various residues of the heptad repeats, which regulates the 
binding and dissociation of protein factors to facilitate the appropriate processes (25-27). Besides 
transcription stages, the Pol II CTD phosphorylation also regulates the co-transcriptional RNA 
processing, which includes 5’-end capping, splicing, and 3’-end processing (28-30). 
During early transcription initiation (Figure 1-2a), Pol II with an unmodified CTD is 
recruited to the gene promoter region and form the PIC with the appropriate transcription factors 
(6-8). The Mediator complex, a transcription co-activator, is recruited by the unmodified CTD 
through multiple hydrogen bonds and hydrophobic interactions with high affinity and interacts 
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with the PIC to stabilize and initiate transcription (31, 32). When Ser5 and Ser7 are phosphorylated 
by cyclin-dependent kinase 7 (CDK7; Kin28 in S. cerevisiae), a component of the general 
transcription factor TFIIH, the hydrogen bonds between the Mediator complex and Pol II CTD are 
possibly disrupted, which leads to the escape of Pol II from the promoter, and early elongation is 
therefore commenced (33, 34) (Figure 1-2b). 
At early transcription elongation, the promoter-proximal pausing of Pol II is released by P-
TEFb phosphorylation to trigger productive elongation (Figure 1-2c) (12, 13). Besides protein 
factors, P-TEFb also phosphorylates Ser2 of Pol II CTD, which directly recruits several elongation 
factors, such as the transcription elongation complex RNA polymerase II-associated factor (PAF1) 
(35-39). In addition, other CTD kinases have been reported to function during transcription 
elongation, such as bromodomain-containing protein 4 (BRD4), cyclin-dependent kinase 12 
(CDK12), and cyclin-dependent kinase 13 (CDK13) (40-42). When Pol II CTD Ser5 
phosphorylation level reaches a maximum in early elongation, the mRNA capping complex is 
recruited by Ser5P, and the interactions allosterically activate the capping complex (43, 44). 
Increased levels of Ser5P also promote the recruitment of the spliceosome near 3ʹ splice sites in 
yeast and mammals (29, 45, 46). 
Transcription termination and the coupled 3’-end RNA processing are regulated by 
phosphorylation of multiple residues on the Pol II CTD. In human, Ser2 and Ser7 are the major 
sites of phosphorylation at the 3′-ends of genes, and Ser7P of the Pol II CTD is required for the 
recruitment of the Integrator complex and thus for snRNA transcription and processing (47-49). 
In S. cerevisiae, Ser2, Thr4, and Tyr1 of the Pol II CTD are subjected to phosphorylation to 
regulate the recruitment of transcription termination factors to Pol II (Figure 1-2d). Ser2P 
contributes greatly to the recruitment of protein 1 of cleavage and polyadenylation factor I (Pcf11), 
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which would interact and recruit the CPF and CFI complexes for the 3’-end processing of mRNAs 
(30, 50, 51). Ser2P and Thr4P bind to regulator of Ty1 transposition protein 103 (Rtt103), which 
is involved in the recruitment of exonuclease Rat1 and Rai1 for RNA degradation (52-54). The 
phosphorylated Tyr1 prevents the binding of Rtt103 and Pcf11 to the Pol II CTD in vitro to prevent 
premature termination (29, 55), and the Tyr1P levels decline before the PAS in yeast cells to ensure 
the appropriate timing for the recruitment of the transcription termination protein factors (55, 56). 
The phosphorylation levels of the Pol II CTD residues are different for the regulation of 
transcription termination of non-coding RNAs through the NNS complex in S. cerevisiae (Figure 
1-5). The nuclear pre- mRNA downregulation protein 1 (Nrd1) of the NNS complex is recruited 
to Pol II CTD through binding to Ser5P (57, 58), and the helicase splicing endonuclease 1 (Sen1) 
of the complex binds to Ser2P of the Pol II CTD (59). After triggering transcription termination, 
the NNS complex will also recruit the exosome to process non-coding RNAs and proceed with 
degradation (Figure 1-5c) (60-62). It was recently reported that Tyr1 of the Pol II CTD is required 
for the transcription termination of ncRNAs (63). Although the detailed mechanism is unclear, it 
was observed that Tyr 1 mediates pausing in the 5'-end of genes, which is important for efficient 
NNS-dependent termination (63). 
Overall, the Pol II CTD undergoes dynamic post-translational modifications throughout 
eukaryotic transcription, which forms an elaborate yet precise system to regulate the involvement 
of various transcription-related protein factors in different transcription stages. Besides 
phosphorylation, the Pol II CTD is also subjected to methylation, ubiquitination, and acetylation 
of non-consensus Lys and Arg residues, which regulates processes such as R-loop resolution, 




Figure 1-2. Transcription regulation by the Pol II CTD phosphorylation (adapted from (21)). Four 
steps of the transcription cycle are depicted with the corresponding CTD phosphorylation state and 
associated factors. (a) The core Pol II complex is recruited to the promoter with an unphosphorylated CTD 
that interacts with the Mediator complex, which has a high affinity for unphosphorylated CTD. (b) 
Phosphorylation of Ser5 and Ser7 of the CTD disrupt the interactions of Pol II with the Mediator complex 
and Pol II escapes from the promoter. During promoter-proximal pausing of Pol II downstream of the 
transcription start site (TSS) at early elongation, Pol II is bound by negative elongation factor (NELF) and 
DRB sensitivity-inducing factor (DSIF). The positive elongation factor B (P-TEFb) phosphorylate NELF, 
DSIF, and Ser2, which triggers the release of NELF and the transition into productive transcription 
elongation. (c) During productive elongation, the CTD contains lower levels of Ser5P and Ser7P and higher 
levels of Ser2P, which promotes the recruitment of many protein factors that regulate elongation and co-
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transcriptional processes. (d) When the polyadenylation signals (PAS) are recognized, Ser2P and Thr4P 
levels increase and transition Pol II into termination for mRNAs. The transcription termination factors and 
3’-end processing factors were recruited, which release Pol II and nascent RNA from the template DNA. 
For non-coding RNAs (ncRNAs), Ser2P and Ser5P recruit Sen1 and Nrd1 of the Nrd1-Nab3-Sen1 (NNS) 
complex, which will recruit the exosome for further 3'-end processing and degradation of transcripts (not 
shown). 
 
1.3 Transcription termination of mRNAs in yeast 
 Most mRNAs undergo Pol II transcription termination through the PAS-mediated pathway, 
which couples with 3’-end cleavage and polyadenylation of the nascent RNA transcripts (Figure 
1-3) (18). Three sub-complexes are involved in this process: the cleavage and polyadenylation 
factor (CPF), the cleavage factor IA (CFIA), and the cleavage factor IB (CFIB) (68). CPF is 
composed of three modules: the nuclease module (Ysh1, Cft2 and Mpe1) that cleaves the pre-
mRNA, the poly(A) polymerase module (Cft1, Pfs2, Pap1, Fip1, and Yth1) that adds the poly(A) 
tail, and the phosphatase module (Pta1, Ref2, Pti1, Swd2, Glc7, Ssu72 and Syc1) that regulates 
transcription and the coupled 3′-end processing (69). CFIA consists of two heterodimers: Rna14-
Rna15 and Pcf11-Clp1, and Pcf11 preferably binds to the Ser2P of Pol II CTD (4, 69, 70). CFIB 
contains an RNA-binding protein Hrp1, which is tightly associated with CFIA (68).  
Transcription termination and the coupled 3′-end processing is triggered when the cis-
acting elements in the 3′ untranslated region (UTR) of the nascent RNA, which include the UA-
rich upstream efficiency elements, the poly(A) signal that tolerates significant degeneracy with 
AAUAAA being the optimal sequence, and a cleavage site that follows a preferred but not required 
consensus pattern of pyrimidine-adenosine (i.e. CA or UA), are recognized by several subunits of 
the CPF–CF complex, such as Rna15, Cft1, Cft2, Yth1, Mpe1, and Hrp1 (4, 71). After Pol II 
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transcription is paused, the nascent RNA is cleaved by the CPF endonuclease Ysh1, the free 
hydroxyl group on the 3′-end upstream cleavage product is polyadenylated by the CPF-associated 
poly(A) polymerase Pap1 (Figure 1-3b), and the downstream cleavage product is degraded by the 
exosome (Figure 1-3c) (4, 69-72). 
There are two proposed models for the detailed mechanism of transcription termination 
mediated by the CPF-CF complexes (Figure 1-3c). The allosteric model proposes that after the 
poly(A) site is transcribed by Pol II, binding of the termination complex induces a conformational 
change of the elongation complex and leads to dissociation of the elongation protein factors. which 
ultimately leads to termination (73). This model is supported by the observation that Pcf11 is able 
to dissociate the elongation complex in vitro, but yet to be validated in vivo (74). The torpedo 
model states the 5′–3′ exonuclease Rat1, a yeast homolog of XRN2 in human, degrades the 
downstream RNA up to the transcribing Pol II, which leads to the dissociation of the elongation 
complex (52, 75). However, an exonucleolytically inactive mutant of Rat1 and its co-factor Rai1 
can dissociate the elongation complex in vitro after Rtt103, which is a CTD-interacting factor, is 
added and recruits Rat1-Rai1 to the 3′ end of genes, which suggests that degradation of RNAs is 
not crucial in promoting termination (52).  
The CPF-CF transcription termination pathway in yeast is highly similar as the poly(A)-
dependent termination for pre-mRNAs in humans, where the Pol II is paused when CPSF (human 
counterpart of CPF) binds to the poly(A) signal, AAUAAA, in the 3’-UTR of nascent transcripts. 
With the recognition of the downstream GU-rich processing signal, CstF (human counterpart of 
CFI) binds to the Pol II CTD and CPSF and trigger the CPSF-mediated cleavage and 
polyadenylation. The 5′-3′ exoribonuclease XRN2 degrades the downstream RNA product, which 




Figure 1-3. Transcription termination at mRNAs in yeast (adapted from (62)). (a) During transcription 
termination of mRNA-coding genes, components of the CPF and CFI complexes recognize specific 
sequences in the 3ʹ untranslated region (UTR) of the transcript. The CFIA component Pcf11 interacts with 
the Ser2P Pol II CTD through its CTD-interaction domain (CID). (b) Upon endonucleolytic cleavage of the 
transcript at the poly(A) site, poly(A) tails are added by the poly(A) polymerase Pap1. The 5ʹ end of the 
downstream portion of the transcript is then targeted by the Rat1 5ʹ–3ʹ exonuclease. (c) Two alternative 
models are proposed for the mechanism of termination after transcript cleavage. The allosteric model posits 
that loss of elongation factors and/or conformational changes in the polymerase after transcription of the 
poly(A) signal destabilizes the elongation complex. The torpedo model postulates that the Rat1 exonuclease 
(alone or in complex with its cofactor Rai1) is recruited by the CTD-interacting protein Rtt103 and degrades 
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the nascent RNA after cleavage. The interaction of Rat1 with the polymerase leads to the dissociation of 
the elongation complex. ORF: open reading frame; TSS: transcription start site. 
 
1.4 Transcription termination of non-coding RNAs in yeast 
Various non-coding RNAs (ncRNAs) are transcribed by Pol II, such as small nuclear RNAs 
(snRNAs), small nucleolar RNAs (snoRNAs), and cryptic unstable transcripts (CUTs) (2-4). In S. 
cerevisiae, the transcription termination of ncRNAs by Pol II is performed by the Nrd1-Nab3-Sen1 
(NNS) complex (19, 20), which consists of two RNA-binding proteins, Nrd1 and Nab3, and a 
conserved DNA/ RNA helicase protein Sen1 (Figure 1-4) (62).  
Nrd1 was discovered as an essential trans-acting factor known as nuclear pre-mRNA 
downregulation (NRD) protein 1 and is considered a heterogeneous nuclear ribonucleoprotein 
(hnRNP)-like protein due to its RNA recognition module (RRM) with a specific termination 
sequence of GUAA (Figure 1-4) (76, 77). Nrd1 is homologous to the human mRNA processing 
protein factors SCAF4 and SCAF8 (77, 78). Nrd1 also contains an N-terminal Pol II CTD-
interacting domain (CID) that preferably binds to the Ser5P Pol II CTD (57, 58), a dimerization 
domains (DD) for protein interactions, and a C-terminal glutamine/proline (Q/P)-rich domain that 
is associated with amyloid-like filament formation in vitro, although the function of the domain 
and the filament formation is unknown (Figure 1-4) (79). Deletion of the DD or the RRM of Nrd1 
in vivo causes transcription termination or processing defects, such as the read-through of the 
snR13 transcripts (57). Although the CID of Nrd1 was not deleted by itself, the deletion of CID 
and DD showed more severe defects than that of DD alone (57), suggesting that the CID also has 
functional importance in 3’-end processing and transcription termination of ncRNA. 
Nab3 was discovered as a nuclear polyadenylated RNA-binding (NAB) protein from yeast 
that is related to human hnRNP-C (80, 81). Similar to Nrd1, Nab3 is also an hnRNP-like protein 
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with an RRM with a specific termination sequence of UCUU (Figure 1-4) (82). Nab3 also 
possesses a DD and a C-terminal Q/P-rich domain, which is required for cell viability (Figure 1-
4) (82, 83). Nrd1 and Nab3 can form a complex through their DDs, although the interaction 
mechanism remains unknown (84). The Nrd1-Nab3 heterodimer binds to RNA substrates 
cooperatively through their RRMs (76, 82, 84-86).  
Sen1 is a yeast helicase protein that is homologous to the human helicase protein Senataxin 
(87). Sen1 consists of an N-terminal HEAT-repeat domain with a preference for Pol II Ser 2P CTD 
and a C-terminal helicase domain for unwinding duplexes of DNA/RNA (Figure 1-4) (59, 88). 
Sen1 is a member of the helicase superfamily 1B (SF1B), which also includes Upf1 and IGHMBP2, 
and the members share a conserved helicase domain (88-90). Interactions between Sen1 and Nab3 
have been reported, but the detailed mechanism is obscure (84). Besides ncRNA transcription 
termination (91), Sen1 also functions in R-loop resolution (92, 93), pre-mRNA transcription 
termination (94, 95), transcription-coupled DNA repair and RNA processing (96). Interestingly, 
despite the multifunctionality of Sen1, only around 125 molecules of Sen1 are present per yeast 
cell, in contrast to Nab3 and Nrd1, which are present at 5,800 and 19,600 molecules per cell (97), 




Figure 1-4. Domain organizations of S. cerevisiae Nrd1, Nab3, and Sen1. The domains are given 
different colors, CID (yellow): CTD-interacting domain, DD (blue): dimerization domain, RRM (orange): 
RNA-recognition module, HEAT repeat (red): HEAT-repeat domain, Helicase (cyan): helicase domain. 
 
During transcription termination, Sen1 and Nrd1 are recruited by the Ser2P and Ser5P of 
Pol II CTD, and Nab3 is recruited through interactions with Nrd1 (Figure 1-5a) (84). When the 
termination sequences in the 3’-end regions of nascent ncRNA transcripts, which are mostly 
clustered GUAA/G and UCUU and are associated with AU-rich sequences that contribute to the 
efficiency of termination (98), are recognized by Nrd1 and Nab3, the helicase Sen1 is speculated 
to remove RNA from Pol II and trigger termination by destabilizing the RNA-DNA hybrid and 
collapsing the transcription bubble (Figure 1-5b) (19, 63, 76, 82, 99). Although the mechanism is 
still not understood, Sen1 alone can dissociate an elongation complex in vitro, preferentially at 
pause sites and requires ATP hydrolysis and recognition of the nascent RNA (100). 
The NNS-mediated transcription termination pathway couples tightly with the multimeric 
Trf4-Air2-Mtr4 polyadenylation complex (TRAMP) and the exosome for 3¢-end trimming of 
stable ncRNAs and rapid degradation of unstable ncRNAs (Figure 1-5c) (101-104). Nrd1 recruits 
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Trf4, a poly(A) polymerases subunit of the TRAMP complex, through the interactions between 
the Nrd1 CID and the Nrd1-interacting motif (NIM) of Trf4, which are mutually exclusive with 
the interactions between Nrd1 CID and Pol II Ser5P CTD (60, 61). Trf4 recruits the exosome via 
interactions with Rrp6 and performs polyadenylation on the ncRNA transcripts, which, drastically 
different from the polyadenylation of mRNAs, trigger degradation by the exosome (60, 105). The 
two 3’-5’ exoribonucleases, Rrp6 and Dis3, of the exosome are responsible for trimming the 3ʹ-
end of snRNA and snoRNA precursors for maturation and complete degradation of CUTs (105, 
106). It's still not clear how the ncRNAs are recognized and subjected to 3'-end trimming or 
degradation, but it was speculated that stable snRNA and snoRNA precursors contain a secondary 
or tertiary structure to block exoribonuclease activity at the appropriate site (107). The Nrd1 CID 
also interacts with Mpp6, a cofactor of the nuclear exosome involved in 5.8S rRNA maturation, 
suggesting the NNS complex could also be involved in rRNA transcription termination by Pol I 
(61). 
In conclusion, the important protein factors involved in the NNS-mediated transcription 
termination pathway and the coupled RNA processing and degradation processes have been 
identified. However, how Nrd1, Nab3, and Sen1 interact with one another during the processes 
and how they function to mediate the pathway is still obscure. Therefore, information regarding 
the interaction and functional mechanism of the NNS complex will contribute to our understanding 
of the transcription termination of ncRNAs in yeast, and will also shed light on the mechanism of 





Figure 1-5. Transcription termination at ncRNAs in yeast (adapted from (62)). (a) During termination 
at non-coding RNA (ncRNA) genes, the Nrd1–Nab3–Sen1 (NNS) complex is recruited to the elongation 
complex through the recognition of specific motifs on the nascent RNA by Nrd1 and Nab3, and the 
interaction of the Nrd1 CID with the Ser5P Pol II CTD. The RNA and DNA helicase Sen1 interacts with 
the Ser2P Pol II CTD. (b) Sen1 is then loaded onto the RNA, where it uses the energy of ATP hydrolysis 
to remove RNA from Pol II and trigger termination by destabilizing the RNA-DNA hybrid and collapsing 
the transcription bubble. (c) The RNA-bound Nrd1-Nab3 heterodimer interacts with the TRAMP (Trf4–
Air2–Mtr4) complex through the Nrd1 CID, which promotes polyadenylation of the transcript and its 
degradation or processing by the exosome and Rrp6. Pi: inorganic phosphate. 
 
1.5 Previous structural studies of the NNS complex 
Subunits of the NNS complex were identified as proteins factors involved in RNA 
processing in 1994 (80). Since then, structures of the components of the NNS complex have been 
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reported, which were obtained either from X-ray crystallography or nuclear magnetic resonance 
spectroscopy (NMR) (57, 60, 76, 82, 88).  
The crystal structure of the CID of Nrd1 was the first structural study characterizing the 
NNS complex (Figure 1-6a) (57). The Nrd1 CID consists of eight a-helices, which forms a right-
handed superhelix containing three pairs of antiparallel a-helices and a C-terminal helix. The 
structure is highly similar to the CIDs of Pcf11 and Rtt103 (30, 51, 57). The NMR structure of the 
Nrd1 CID in complex with a Ser5P Pol II CTD peptide was also reported (Figure 1-6b), in which 
the Nrd1 CID took essentially the same conformation as the free form (57, 58). The CTD peptide 
adopts a β-turn conformation and fits into a hydrophobic groove of the Nrd1 CID, which is also 
similar to the binding of CTD on Pcf11 and Rtt103 (30, 51).  
The structure of the RNA-binding domain (RBD) of Nrd1 in complex with its RNA 
substrate (GUAA) shows two domains: the RRM is in the canonical a/b topology that folds into a 
four-stranded, anti-parallel b-sheet packed against two a-helices; another domain is formed from 
two discontinuous segments whose sequences flank the RRM, and thus named the split domain 
(SD) (Figure 1-6c) (86). The backbone of the RNA nucleotides form planar stacking interacts with 
the RRM and SD, and the RNA base specificity is achieved through hydrogen bonds to the protein 
(86). The interaction interface of RRM and SD is crucial for high RNA binding affinity, and both 
domains are essential for cell viability (86). The interactions between the Nrd1 CID and the Nrd1-
interacting motif (NIM) of Trf4, a subunit of the TRAMP complex, was also characterized 
structurally (60). The N-terminal region of the Trf4 NIM consists of many negatively charged 
residues, which form ionic interaction with a positively charged patch of the Nrd1 CID, while the 
C-terminal region of the Trf4 NIM docks into a hydrophobic pocket of the Nrd1 CID (Figure 1-
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6d) (60). The Nrd1 CID is identical as the free form, and Trf4 NIM peptide binds to Nrd1 in a 
similar but different mode from the Pol II CTD peptide (Figure 1-6d) (57-60). 
 
 
Figure 1-6. Structures of the CID and RNA-binding domain (RBD) of Nrd1 (adapted from (57, 58, 
86)). (a) Ribbon presentation of the Nrd1 CID. The bound sulfate ion contacting the loop between helix 1 
and helix 2 is represented as a stick model, and the missing loop between helices 4 and 5 is modeled as a 
random coil in cyan. (b) Overlay of the 20 lowest-energy structures of the Nrd1 CID in complex with Ser5P 
Pol II CTD. The backbone of the Nrd1 CID and the CTD peptide are shown in black and red, respectively. 
(c) Structure of the Nrd1 RBD in complex with an RNA substrate (GUAA). Nrd1 RRM is represented as 
surface and colored in pink and the split domain (SD) flanking the RRM in blue. The RNA is shown as 
sticks. (d) Solution structure of Nrd1 CID in complex with the Trf4 Nrd1-interacting motif (NIM) peptide. 
The NIM peptide is represented in yellow sticks, and the protein is shown as a gray ribbon model. Protein 
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residues that form hydrophobic contacts and putative hydrogen bonds to the NIM peptide are shown in 
magenta sticks. 
 
 The crystal structure of Nab3 RRM in complex with its specific RNA substrate was also 
reported, although only the UCU trinucleotide was observed in the density (Figure 1-7a) (82). The 
RRM folds into the conformation of a canonical RRM, which is highly similar to the free form 
Nab3 RRM and the Nrd1 RRM, (82, 86). Unlike the Nrd1 RRM (86), Nab3 RRM is sufficient for 
binding and binds to the RNA substrate mainly through interactions between the side chains of the 
beta strands and the bases of the RNA, and only one hydrogen bond was observed between the 
protein and the phosphate backbone of the trinucleotide (82). The binding specificity of C2 
nucleotide is achieved by the docking of the nucleotide through hydrophobic interactions and 
hydrogen bonds into a groove formed by side chains of the protein residues, which contributes to 
discrimination for pyrimidine nucleotides against purines. In addition, a network of hydrogen 
bonding guarantees specificity for a cytidine at this position. The other two nucleotides are also 
specifically recognized through hydrogen bonds and hydrophobic interactions with the side chains 
of the RRM (82). 
 As a member of the SF1B helicase family, which usually contains two RecA domains 
(RecA1 and RecA2) for nucleic acid binding and ATP hydrolysis, as well as  two SF1B-specific 
subdomains (1B and 1C) for RNA binding modulation, the crystal structure of the Sen1 helicase 
domain in complex with ADP shows a similar but different conformation from the helicase 
domains of Upf1 and IGHMBP2 (Figure 1-7b) (88-90). The ADP is sandwiched by a cleft between 
two RecA domains side by side. Subdomains 1B is packed on one side of RecA through 
hydrophobic interactions, which form the a-helical “stalk” and a b-barrel fold (“barrel”), and 
subdomain 1C is packed on the other side of RecA, which forms an a-helical 'prong' (Figure 1-7b) 
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(88, 108). The distinct feature of the structure of Sen1 helicase is the ‘brace’, which is not observed 
in the helicase domain of Upf1 or IGHMBP2 (88-90). The ‘brace’ stabilizes the overall fold of the 
protein through a network of hydrophobic interactions and other Van der Waals interactions with 
the RecA1 domain, the “stalk”, and the “barrel”, and is functionally important in vitro and in vivo 
(88). The helicase core of Sen1 is sufficient for unwinding activity and transcription termination 
in vitro, but other domains could be involved in the recruitment of other protein factors and the 
RNA substrates in vivo (88). 
 
 
Figure 1-7. Crystal structures of Nab3 RRM in complex with RNA and Sen1 helicase domain 
(adapted from (82, 88)). (a) Nab3-RRM (yellow) bound to an RNA substrate (magenta), and the UCU 
trinucleotide is observed in the density. The Nab3-RRM is represented as ribbon and the bound RNA 
nucleotides as stick model. Electron density from a 2Fo–Fc map contoured at 1s for the RNA is illustrated 
as a blue mesh. (b) Ribbon presentation of Sen1helicase domain in complex with ADP. Dotted lines indicate 
disordered loops not modeled in the present structure. The RecA1 and RecA2 domains are in yellow, the 
“stalk” in gray, subdomain 1B (the “barrel”) in orange and subdomain 1C (the “prong”) in red. The N-
terminal “brace” is shown in blue. 
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In conclusion, although structures of the domains of the subunits of the NNS complex have 
been reported, there is still no structural information regarding how Nrd1, Nab3, and Sen1 interact 
with one another to form the NNS complex or how the NNS complex function in transcription 
termination and the coupled RNA processing and degradation. Therefore, information on the 
interaction and functional mechanism of the NNS complex could bridge the gap in understanding 
the process of transcription termination in yeast. The novel structural, biochemical, and functional 
insights could also shed light on the mechanism of transcriptional termination and the coupled 




























Structural studies of the Nrd1-Nab3-Sen1 complex in yeast 
 
2.1 Introduction 
In eukaryotic transcription by RNA polymerase II (Pol II), transcription termination is an 
important process to preventing RNA polymerase interference with neighboring DNA elements, 
recycling RNA polymerase, regulating gene expression via premature termination of transcription, 
and promoting RNA 3′-end processing (73, 109-112). This process, which collapses the 
transcription bubble and releases the Pol II and nascent RNA from the template DNA, is carried 
out with the facilitation of different transcription factors (4). In S. cerevisiae, there are two 
transcription termination pathways: the polyadenylation signal (PAS) mediated processing for 
mRNAs from coding genes that involves the cleavage and polyadenylation factor (CPF) and the 
cleavage factor I A and B (CFI) (18), and the Nrd1-Nab3-Sen1 (NNS)-mediated processing for 
most non-coding RNAs (ncRNAs) that involves components of the CPF, CFI, and the NNS 
complex, which will be focused on here (19, 20).  
Nrd1 and Nab3 can form a complex through their dimerization domains (DD) and bind to 
RNA cooperatively through their RNA recognition modules (RRMs) (76, 82, 85, 86) (Figure 2-1). 
The binding sites on ncRNAs have been identified as GUAA for Nrd1 and UCUU for Nab3, and 
the binding was shown to be highly specific (76, 82). Nrd1 also contains an N-terminal Pol II 
CTD-interacting domain (CID) that prefers the Ser5P C-terminal domain (CTD) (57, 58) (Figure 
2-1). Deletion of the DD or the RRM of Nrd1 in vivo causes transcription termination or processing 
defects, such as the read-through of the snR13 transcripts (57). Although the CID of Nrd1 was not 
deleted by itself, the deletion of CID and DD showed more severe defects than that of DD alone 
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(57), suggesting that the CID also has functional importance in 3’-end processing and transcription 
termination of ncRNA. Having a preference for Pol II Ser 2P CTD through the HEAT-repeat 
domain (59), the helicase Sen1, a yeast homolog of the human helicase protein Senataxin (87), is 
speculated to remove nascent RNA from Pol II and trigger termination by destabilizing the RNA-
DNA hybrid and collapsing the transcription bubble (19, 63, 99) (Figure 2-1). Nrd1-Nab3-Sen1 
(NNS) couples tightly with the TRAMP complex for 3¢-end trimming of ncRNAs and degradation 
of unstable RNAs (101-104), which is mediated by the interaction between Nrd1 CID and Trf4, a 
subunit of the TRAMP complex (60, 61). The Nrd1 CID also interacts with Mpp6, a cofactor of 
the nuclear exosome (61). Besides ncRNA transcription termination (91), Sen1 also functions in 
R-loop resolution (92, 93), pre-mRNA transcription termination (94, 95), transcription-coupled 
DNA repair and RNA processing (96). Interestingly, despite the multifunctionality of Sen1, it is 
present in cells at a much lower abundance than Nrd1 or Nab3 (97, 113), and the reason for this 
observation is still unknown.  
Structural studies of the NNS complex began more than a decade ago when the crystal 
structure of the Nrd1 CID was reported (57). Several years later, the structures of the Nrd1 RRM 
and Nab3 RRM in complex with their respective RNA substrates were also determined (76, 82). 
Since Sen1 is a protein of high molecular weight, which adds difficulty in crystallization, the 
crystal structure of the helicase domain was recently reported (88). However, there is still no 
structural information regarding how Nrd1, Nab3, and Sen1 interact with one another to form the 
NNS complex is currently not well understood. 
Overall, although the key players in the transcription termination pathway for ncRNA have 
been identified, and the structural information of individual proteins has been obtained, the 
interaction and functional mechanism of the NNS complex and the regulatory mechanism of the 
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transcription termination processes of ncRNA have remained unclear. Therefore, more structural 
and biochemical information regarding the NNS complex would contribute to a deeper 
understanding of this pathway.  
In order to understand the molecular basis of the interaction among subunits of the NNS 
complex, we identified three Nrd1-interacting motifs (NIMs) in the C-terminal segment (CTS) of 
Sen1, and determined the crystal structures of the CID of S. cerevisiae Nrd1 in complex with each 
of the three Sen1 NIM peptides (114). The crystal structures revealed the detailed interaction 
mechanism between Nrd1 and Sen1, which is highly similar to that between Nrd1 and Trf4 (60). 
We and our collaborator Stephen Buratowski at Harvard Medical School also performed 
biochemical and functional studies, which confirmed the interactions through the NIMs in vitro 
and in vivo. Although neither the Sen1 NIMs nor Nrd1 CID is essential for supporting viability, 
Sen1 NIM deletions do show termination defects in a reporter assay. The conservation of these 








Figure 2-1. Domain organizations of S. cerevisiae Nrd1, Nab3, and Sen1. The domains are given 
different colors, CID (yellow): CTD-interacting domain, DD (blue): dimerization domain, RRM (orange): 
RNA-recognition module, HEAT repeat (red): HEAT-repeat domain, Helicase (cyan): helicase domain. 
 
2.2 Experimental procedures 
2.2.1 Protein expression and purification 
S. cerevisiae Nrd1 CID (residues 6-151) and Sen1 constructs from S. cerevisiae, S. pombe, 
and K. lactis were sub-cloned into the pET28a or pET26b vector (Novagen). The recombinant 
protein, with an N- or C-terminal hexahistidine tag, was over-expressed in E. coli BL21 Star (DE3) 
cells (Novagen), which were induced with 0.4 mM IPTG and allowed to grow at 16 °C for 16–20 
h.  
Complexes of  K. lactis, Z. rouxii, and C. glabrata Nrd1 and Nab3 were co-expressed in E. 
coli BL21 Star (DE3) cells (Novagen). Nrd1 was sub-cloned into the pET28a vector (Novagen) 
with an N-terminal hexahistidine tag, and Nab3 was sub-cloned into the pCDFDuet vector 
(Novagen) without any tag. The two plasmids were co-transformed into BL21 Star (DE3) cells 
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(Novagen), which were over-expressed and induced with 0.4 mM IPTG and allowed to grow at 
16 °C for 16–20 h.  
Constructs of Sen1 HEAT domain from S. cerevisiae, S. pombe, and K. lactis were 
expressed in insect cells using Multibac technology (115) (Geneva Biotech). Sen1 was sub-
cloned into the Multiple Cloning Sites 1 (MCS1) of the pFL vector with an N-terminal 
hexahistidine tag. The bacmid expressing Sen1 was generated in DH10EMBacY competent cells 
(Geneva Biotech) by transformation. 
Complexes of S. cerevisiae Nrd1 and Nab3 were co-expressed in insect cells using 
Multibac technology (115) (Geneva Biotech). Nab3 and Nrd1 were sub-cloned into the Multiple 
Cloning Sites 1 (MCS1) and Multiple Cloning Site 2 (MCS) of the pFL vector, respectively, and 
a 6×His tag was added to the N-terminus of Nab3. The bacmid co-expressing Nrd1 and Nab3 
was generated in DH10EMBacY competent cells (Geneva Biotech) by transformation.  
For expression in insect cells, the baculovirus was generated by transfecting the bacmid 
into Sf9 cells using Cellfectin II (Thermo Fisher Scientific). P1 virus was cultured at 27 °C for 5 
d, and P2 virus for large-scale infection was amplified from the P1 virus in 50 mL of Sf9 cells at 
27 °C for 3 d. One liter of High5 cells (1.8 × 106cells·mL−1) cultured in ESF 921 medium 
(Expression Systems) was infected with 25 mL of P2 virus at 27 °C with constant shaking. Cells 
were harvested after 48 h by centrifugation at 500 × g for 15 min.  
For purifications of all the constructs, the soluble protein was purified by nickel-charged 
immobilized-metal affinity chromatography, heparin chromatography or ion-exchange 
chromatography, and size-exclusion chromatography. The purified Nrd1 CID protein sample was 
concentrated in a buffer containing 20 mM Tris (pH 7.0), 150 mM NaCl, 10 mM DTT. All the 
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other purified proteins were concentrated in a buffer containing 20 mM Tris (pH 7.0), 200 mM 
NaCl, 10 mM DTT. The protein samples were stored at –80 °C.  
 
2.2.2 Protein crystallization 
Crystals of Nrd1 CID-Sen1 NIM complex were grown at 20 °C with the hanging-drop 
vapor diffusion method. Nrd1 CID protein solution was at 20 mg/ml concentration, and the protein 
was mixed with Sen1 NIM peptides (GL Biochem) at a molar ratio of 1:10. The reservoir solution 
contained 0.1 M sodium citrate (pH 4.0), 1 M lithium chloride and 20% (w/v) PEG 6000. Fully-
grown crystals were obtained one day after set-up. The crystals were cryoprotected in the 
crystallization solution supplemented with 15% (v/v) ethylene glycol and flash-frozen in liquid 
nitrogen for data collection at 100 K.  
 
2.2.3 Data collection and processing 
X-ray diffraction data sets were collected at a wavelength of 0.979 Å on a Pilatus-6MF 
pixel array detector at the 24-ID-C beamline of the Advanced Photon Source (APS). The 
diffraction images were processed and scaled with XDS (116).  
 
2.2.4 Structure determination and refinement 
The structures were solved by molecular replacement with the program Phaser-MR in 
PHENIX (117, 118). The crystal structure of S. cerevisiae Nrd1 CID (PDB code 3CLJ) (57) was 
used as the search model. Manual model rebuilding was carried out with Coot (119). The structure 
refinement was performed with the program PHENIX, with translation, libration, and screw-
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rotation (TLS) parameters. The data processing and refinement statistics are summarized in Table 
2-1.  
 
Table 2-1. Summary of crystallographic information 
 CID+NIM1 CID+NIM2 CID+NIM3 
Data collection    
Space group C2221 C2221 C2221 
Cell dimensions    
a, b, c (Å) 103.4, 109.1, 86.7 98.9, 102.5, 115.5 98.7, 103.0, 115.4 
a, b, g (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution range (Å)1 50-2.1 (2.2-2.1) 50-2.0 (2.1-2.0) 50-2.8 (3.0-2.8) 
No. of observations 185,949 175,380 48,822 
No. of unique reflections 27,909 39,419 14,439 
Rmerge (%) 8.4 (67.9) 8.0 (48.7) 14.7 (48.8) 
I/sI 16.8 (5.4) 12.2 (3.1) 7.3 (2.8) 
CC1/2    
Completeness (%) 96.2 (96.7) 98.1 (96.9) 97.1 (97.2) 
Redundancy 6.7 (6.9) 4.4 (4.3) 3.4 (3.4) 
Refinement    
Resolution range (Å) 46-2.1 (2.2-2.1) 45-2.0 (2.1-2.0) 45-2.8 (2.9-2.8) 
No. of reflections 27,890 39,414 14,426 
Rwork (%) 18.6 (23.0) 17.9 (25.2) 23.7 (29.1) 
Rfree (%) 20.4 (28.6) 22.6 (29.2) 30.0 (31.3) 
No. atoms    
Protein 2,428 3,561 3,560 
Cl 0 2 2 
Water 126 260 – 
B-factors    
Protein 42.7 35.4 40.9 
Cl – 23.5 31.2 
Water 45.0 40.2 – 
RMS deviations    
Bond lengths (Å) 0.006 0.007 0.008 
Bond angles (°) 0.73 0.76 1.10 
Ramachandran plot 
statistics (%)    
Most favored 
region 98.29 98.85 97.92 
Additional 
allowed region 1.37 1.15 2.08 
1The numbers in parentheses are for the highest resolution shell. 
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2.2.5 Fluorescence anisotropy binding assay 
Nrd1 CID mutants were expressed and purified using the same protocol as that for the wild-
type CID. NIM1, NIM2, NIM3, NIM2 mutants, Pol II Ser5p CTD and N-terminally 5-
carboxyfluorescein (5-FAM) labeled NIM2 peptides were obtained for fluorescence anisotropy 
(GL Biochem) (Table 2-2). For direct binding assays, 5 nM 5-FAM-labeled NIM2 peptide was 
titrated with wild-type and mutants of Nrd1 CID at increasing concentrations. For competition 
assays, complex of 5 nM 5-FAM-labeled NIM2 peptide and 3 µM wild-type Nrd1-CID was titrated 
with unlabeled NIM1, NIM2, NIM3, NIM2 mutants and Pol II Ser5p CTD peptides at increasing 
concentrations. The measurements were conducted on a Synergy Neo2 Hybrid Multi-Mode Reader 
(Biotek). Samples were excited at 485 nm and emissions were recorded at 528 nm. Measurements 
were performed in triplicates at room temperature in 20 mM Tris (pH 7.0), 200 mM NaCl, 5 mM 
DTT. The binding curves were fitted by GraphPad Prism (GraphPad Software, La Jolla) using the 
hyperbolic equation for direct binding and the analytical model for competitive binding (120).  
 










Pol II CTD SPT(pS)PSYSPT(pS)PS1 




2.2.6 Mixing assay 
For mixing assays of Nrd1 and Sen1, mixtures of purified proteins were incubated on ice 
for 1 h and separated on Superose 6 Increase 10/300 GL column (GE Healthcare) in 20 mM Tris 
(pH 7.0), 200 mM NaCl, 5 mM DTT.  
For mixing assays of Nrd1-Nab3 complex with snR13 RNA, mixtures of purified proteins 
and RNA were incubated on ice for 1 h and separated on Superose 12 Increase 10/300 GL column 
(GE Healthcare) in 20 mM Tris (pH 7.0), 200 mM NaCl, 10 mM DTT.  
 
2.2.7 Pull-down assay 
Various regions of S. cerevisiae Sen1 CTS and its mutants and K. lactis Sen1 CTS were 
sub-cloned into the pET28a-SUMO vector unless specified otherwise. The recombinant Sen1 
proteins would contain an N-terminal hexahistidine tag followed by a SUMO tag unless specified 
otherwise. The plasmid was co-transformed with one for un-tagged S. cerevisiae Nrd1 CID 
(residues 6-151) or K. lactis Nrd1 CID (residues 1-155) and over-expressed in E. coli BL21 Star 
(DE3) cells (Novagen). The culture was induced with 0.4 mM IPTG and allowed to grow at 16 °C 
for 16–20 h. The soluble protein was incubated with nickel-charged resin for 1 hour at 4 °C, 
washed with a buffer containing 20 mM Tris (pH 7.0), 200 mM NaCl, 20 mM imidazole and eluted 
with a buffer containing 20 mM Tris (pH 7.0), 200 mM NaCl, 150 mM imidazole. The eluate was 
mixed with protein dye and run on an SDS-PAGE gel. 
 
2.2.8 Mutagenesis of Sen1 CTS 
Site-specific tyrosine-to-alanine mutations of Sen1-CTS were generated following the 
QuikChange2 protocol (Stratagene) and sequenced for verification of the correct incorporation of 
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the target mutations. The proteins were overexpressed and purified following the same protocol as 
that for the wild-type Sen1 proteins.  
 
2.2.9 Thermal shift assay 
The thermal stability of the HEAT repeat domain of S. cerevisiae Sen1 (19-937) was 
analyzed at various temperatures using the Mx3005P Real-Time PCR system (Stratagene). The 
assay was performed in duplicate and contained final concentrations of 20 mM Tris (pH 7.0), 200 
mM NaCl and 10 mM DTT. The protein was mixed with the fluorescence dye (SYPRO orange; 
Invitrogen) for monitoring protein unfolding. The temperature was increased from 25 to 99 °C in 
1 °C intervals over a 75-min period. Fluorescence values were normalized to the maximum and 
the minimum of the curve. 
 
2.2.10 Limited proteolysis 
The protein sample was diluted to 1 mg/ml and incubated at room temperature with trypsin 
or chymotrypsin at a 1:1000 weight ratio in a buffer containing 20mM Tris (pH 8.0) and 10mM 
CaCl2. Protein samples were taken at various time points (0, 10, 30, 60, 120, 240, and overnight). 
The protein samples were mixed with the protein dye, boiled and run on an SDS-PAGE gel.  
 
2.2.11 Electrophoretic Mobility Shift Assay (EMSA) 
snR13 RNA oligos (AAUCUUAGUAAUC) with 3’ 6-FAM label (IDT) was dissolved in 
DEPC-treated water. The EMSA was performed with 2 µM labeled RNA and increasing 
concentrations of protein. The reactions were incubated at room temperature for 30 min in a 10-
µL volume containing 20 mM Tris (pH 7.0), 200 mM NaCl, 1 mM MgCl2, 1 mM DTT, 5% (v/v) 
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glycerol, and 0.1 mg/ml BSA. The samples were then supplemented with 1 µL of 50% (v/v) 
glycerol and run on pre-chilled 0.6% (w/v) TAE agarose gels at 140 V for 30 min. The gels were 
visualized on a Typhoon FLA 7000 (GE Healthcare). 
 
2.3 Results and discussions 
2.3.1 Mapping the interaction region of Sen1 with Nrd1 
It was reported that the C-terminal segment (CTS) of S. cerevisiae Sen1 (ScSen1) (residues 
1876-2231) interacts strongly with Nab3 (84). This segment has no predicted secondary structures 
and no conservation among Sen1 homologs. However, from mixing assays, no interaction was 
observed for purified K. lactis Sen1 CTS with Nab3 and Nrd1 constructs that cover the region 
from the dimerization domain (DD) to the C-terminus (Figures 2-1, 2-2).  
 
 
Figure 2-2. Mixing assays showed no interaction between K. Lactis Sen1 CTS and Nab3 segments. 
Purified K. Lactis Sen1, Nrd1, and Nab3 proteins were run on a size-exclusion chromatography column, 




Surprisingly, interactions were observed among all three proteins when S. cerevisiae Sen1 
CTS (residues 1892-2092) and full-length Nrd1-Nab3 were used for mixing assays (Figure 2-3a). 
Comparing the constructs used in these experiments, it was hypothesized that the CID of Nrd1 
mediated the formation of the complex. To confirm this hypothesis, mixing assays demonstrated 
that deletion of the CID abolished complex formation (Figure 2-3b), and mixing of purified Nrd1 
CID and Sen1 CTS followed by size-exclusion chromatography directly confirmed the interaction 
regions (Figure 2-3c).  
 
 
Figure 2-3. S. cerevisiae Sen1 CTS interacts with Nrd1-CID. Purified S. cerevisiae Sen1, Nrd1, and 
Nab3 proteins were run on a size-exclusion chromatography column, and the indicated fractions were 
resolved by SDS-PAGE.  
 
To map the region of S. cerevisiae Sen1 (ScSen1) CTS that is required for interaction with 
Nrd1 CID, various fragments of the CTS residues 1892-2092 were co-expressed with the CID 
(Table 2-3). Interactions between the two proteins were indicated by pull-down experiments after 
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co-expression in E. coli (Figure 2-4a, b). Pull-down assays showed that Sen1 residues 1892-2062 
could pull down CID but residues 1892-2052 could not (Figures 4a-c), which suggested residues 
2052-2062 are crucial for binding. Residues 2052-2062 of Sen1 have the sequence 
DDDEDDYTPSI, and we realized that it is remarkably similar to the Nrd1 interaction motif (NIM) 
in Trf4 (Figure 2-4d) (60, 61), suggesting that ScSen1 also contains a NIM. The Tyr and Pro 
residues in Trf4 are important for binding the Nrd1 CID (60), and these residues are also present 
in the NIM of ScSen1. 
 
Table 2-3. Summary of constructs of S. cerevisiae Sen1 CTS 
Name Tag Vector Start End Total Residue 
M.W. 





Sen1-54 N-His-SUMO pET28a 1892 2092 201 22,294 9.4 0.20 2 2 
Sen1-73 N-His-SUMO pET28a 1892 2032 141 15,651 9.9 0.10 2 2 
Sen1-76 N-His-SUMO pET28a 2025 2092 68 6,662 4.2 0.45 2 2 
Sen1-77 N-His-SUMO pET28a 2033 2092 60 6,662 4.2 0.23 2 2 
Sen1-78 N-His-SUMO pET28a 1984 2092 109 25,566 5.8 0.18 2 2 
Sen1-86 N-His-SUMO pET28a 1892 2042 151 16,750 9.9 0.09 2 2 
Sen1-87 N-His-SUMO pET28a 1892 2052 161 17,861 9.7 0.08 2 2 
Sen1-88 N-His-SUMO pET28a 1892 2062 171 19,012 9.4 0.16 2 2 
Sen1-89 N-His-SUMO pET28a 1892 2072 181 20,049 9.3 0.15 2 2 
Sen1-90 N-His-SUMO pET28a 1892 2082 191 21,155 9.4 0.14 2 2 
 
A multiple sequence alignment of fungal Sen1 sequences aligned residues 2052-2062 of 
ScSen1 with DEDEDDYKLPT of V. polyspora Sen1 (VpSen1), suggesting that this could be 
another NIM. Surprisingly, a motif in the CTS of ScSen1 near residue Tyr1887 (Figure 2-4d) was 
also found just after the helicase domain (Figure 2-1), and its interaction with Nrd1 CID was 
confirmed by pull-down assays (Figure 2-5a, b). The crystal structure of this motif in complex 
with the CID indicates that the Leu residue (rather than the Pro) is important for binding the CID 
(see below). Based on this information, the ScSen1 CTS was re-examined, and another sequence 
motif near residue Tyr2186 (Figure 2-4d) was identified and confirmed by pull-down experiments 
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(Figure 2-5c). Therefore, ScSen1 has three NIMs in its CTS, which were named NIM1, NIM2, 
and NIM3 sequentially based on their locations (Figure 2-5d).  
 
 
Figure 2-4. Mapping of the region in S. cerevisiae Sen1 CTS that interacts with Nrd1-CID. (a, b) His-
tagged Sen1 were co-expressed with untagged Nrd1 CID to map their regions of interaction. Sen1 (1892-
2082) does not contain SUMO, Sen1 (1892-2042) contains two copies of SUMO. P: pellet, E: Ni column 
eluate, FT: flow through. (c) Various segments of Sen1 can (green) or cannot (red) pull down Nrd1 CID. 
The segment that is crucial for the interaction is boxed. (d) Alignment of 15 NIMs found in seven fungal 
species. Also shown is the NIM in Trf4 and the Pol II CTD consensus. Residues in the consensus motif are 




Figure 2-5. Identification of two additional NIMs in S. cerevisiae Sen1. (a-c) His-tagged Sen1 were co-
expressed with untagged Nrd1 CID to map their regions of interaction. P: pellet, E: Ni column eluate, FT: 
flow through. Panels (b) is for K. lactis proteins, and panels (a) and (c) are for S. cerevisiae proteins. (d) 
Domain organizations of S. cerevisiae Sen1. The domains are given different colors, HEAT repeats (gray), 
helicase (light blue). The three NIMs are in red. 
 
The CTS sequences of 12 fungal Sen1 were then examined, and 15 NIMs in 7 fungal 
species were identified with a consensus motif (D/H/N)xYx(P/L), where x is frequently a 
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hydrophilic residue (Figure 2-4d). The Y-2 residue is predominantly Asp, while the Y+2 residue 
is predominantly Pro. Some species have three NIMs, while others have only one or two. Five of 
the fungal species examined, such as C. albicans, D. hansenii, and S. pombe, do not appear to have 
a NIM in the CTS. 
 
2.3.2 Construct design and protein expression 
The recombinant Nrd1 CID domain (residue 6-151) was generated based on previous 
structural studies (57) (Table 2-4).  Since this construct showed a high level of expression and 
solubility from small-scale expression tests in E. coli, this recombinant protein was purified from 
large-scale E. coli culture using Ni-NTA affinity chromatography followed by heparin 
chromatography and Superose 12 size-exclusion chromatography (Figure 2-6). The resulting 
protein was pure and homogeneous, based on the SDS-PAGE gel and the size-exclusion 
chromatography profile (Figure 2-6), which was concentrated to 40 mg/ml for crystallization 
screens. 
 
Table 2-4. Summary of the construct of S. cerevisiae Nrd1 CID domain 
Name Tag Vector Start End Total Residue 
M.W. 





Nrd1-82 N-His pET28a 6 151 146 16,358 7.9 0.79 3 3 
 
2.3.3 Crystal screening and optimization 
The Nrd1 protein samples were incubated with each of three ScSen1 NIM peptides (ScSen1 
NIM1: 1882-EQEDDYKLPMEYIT-1895, ScSen1 NIM2: 2053-DDEDDYTPSISD-2064, ScSen1 
NIM3: 2181-EAEDPYDLNPHPQ-2193) (GL Biochem) at a molar ratio of 1:10. The final protein 
concentration was 20 mg/ml. The protein mix was screened for the crystallization condition that 
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was reported for the structure of S. cerevisiae Nrd1 CID domain (0.1 M sodium citrate, pH 5.5, 
and 1.4 M ammonium sulfate) (57). However, no protein crystal was observed in the condition. 
Therefore, the protein mix was screened for crystallization conditions from ten commercial 
crystallization suites by sitting drop vapor diffusion at 20 °C. Needle-shaped protein crystals 
appeared after one day in 0.1 M sodium citrate (pH 4.0), 1 M lithium chloride, and 20% (w/v) PEG 
6000 (Figure 2-7a). After several rounds of optimization, the crystals from this condition diffracted 
to around 8 Å using the in-house X-ray source. Interestingly, plate-shaped crystal also appeared in 
the same crystallization condition from Nrd1 CID in complex with ScSen1 NIM1 peptide only 
(Figure 2-7b), which diffracted to 2.5 Å using the in-house X-ray source. 
 
 
Figure 2-6. Size-exclusion chromatography of the S. cerevisiae Nrd1 CID (6-151). The eluted fractions 






Figure 2-7. Crystals of Nrd1 CID (6-151) in complex with Sen1 NIM peptides. (a) Needle-shaped 
crystals from 0.1 M sodium citrate (pH 4.0), 1 M lithium chloride, and 20% (w/v) PEG 6000. (b) Plate-
shaped crystals of Nrd1 CID domain in complex with Sen1 NIM1 peptide from the same crystallization 
condition. 
 
2.3.4 Structure determination and characterization 
We have determined the crystal structures of Nrd1 CID in complex with each of the NIMs 
in ScSen1, at up to 2.0 Å resolution (Table 2-1). The structures of CID in the three complexes are 
essentially identical, with rms distance of 0.2-0.3 Å for equivalent Ca atoms between any pair of 
them (Figures 8a, b). The NIMs bind at the same surface depression (Figure 2-8c) as that for Pol 
II CTD (58) and Trf4 NIM (60, 61) (Figure 2-9). Clear electron density for the conserved 
(D/H/N)xYx(P/L) motif was observed in the complexes (Figure 2-10). The remaining residues of 
the NIM peptides were mostly disordered, except the C-terminal residues of NIM1, which are 
stabilized by crystal packing. Therefore, residues outside of the conserved motif do not have strong 






Figure 2-8. Structures of Nrd1 CID in complex with Sen1 NIMs. (a) Overlay of the structures of CID 
in complex with NIM1 (green), NIM2 (cyan), and NIM3 (pink). (b) Overlay of the structures, viewed after 






Figure 2-9. Comparison of the binding modes of other sequence motifs to Nrd1 CID. (a) Overlay of 
the NIM2 complex (cyan) with the Ser5P CTD complex (gray). (b) Overlay of the NIM2 complex (cyan) 
with the Trf4 NIM complex (gray). (c) Overlay of the NIM2 complex (cyan) with the Nrd1 CID in complex 
with residues 139-146 from another molecule by crystal packing (gray). These residues are in helix a7, 
which has become partially unwound. (d) Overlay of the binding modes of NIM2 (cyan) with the Ser5P 
CTD (gray). (e) Overlay of the binding modes of NIM2 (cyan) with the Nrd1 CID residues 139-146 from 








Figure 2-10. Observed electron density for the Sen1 NIMs. Omit Fo–Fc electron density map for (a) 
NIM1 at 2.1 Å resolution, contoured at 2.5s. (b) NIM2 at 2.0 Å resolution, contoured at 2.5s. (c) NIM3 at 
2.8 Å resolution, contoured at 2s.  
 
The NIM assumes a mostly extended conformation and has three major contacts with the 
CID, via the Y0, Y-2 and Y+2 residues (Figure 2-8b). The Y0 residue of the NIM has a central 
role in the interaction with CID. Its side chain aromatic ring interacts with the side chains of Ile29, 
Tyr67 and the Y+2 residue, while its hydroxyl group forms a hydrogen bond with the side chain 
of Asp70 (Figure 2-11a). Asp70 is also involved in a bi-dentate interaction with Arg74. The Y+2 
residue contacts a hydrophobic patch formed by Leu127, Ile130, Tyr67 and the Y0 residue of the 
NIM, and the Asp70-Arg74 ion pair forms one side of the binding site for this residue. The Y-2 
residue has hydrogen-bonding interactions with Ser25 and Ser27, which caps the N-terminus of 
helix a2. If the Y-2 residue is Asp, its side chain can also have favorable interactions with the 
dipole of this helix. 
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With Leu at the Y+2 position, a change in the backbone structure of the Y+1 and Y+2 
residues is necessary to make room for this bulkier side chain compared to Pro (Figure 2-11). The 
binding modes of NIM1 and NIM3, which both have Leu at the Y+2 position, are similar.  
Residues N-terminal to Y-2 are mostly negatively charged in ScSen1 as well as many other 
NIMs (Figure 2-4d). An electro-positive patch in this region of Nrd1 CID (Figure 2-8c) could 
suggest favorable interactions, but these residues in the NIMs are not ordered in the structures. K. 




Figure 2-11. Conformational changes of the Y+1 and Y+2 residues of the Sen1 NIMs. (a) Detailed 
interactions between NIM1 (green) and NIM2 (cyan) and the CID. Hydrogen-bonding interactions are 
indicated with the dashed lines (red). The conformational changes of the Y+1 and Y+2 residues are 
indicated with the red arrow. (b) Overlay of the binding modes of the three NIM peptides.  
 
2.3.5 Binding affinity of Nrd1-CID for Sen1 NIMs 
The structural observations are supported by our mutagenesis and fluorescence anisotropy 
assays. The Kd of the CID-NIM2 complex was 0.56±0.05 µM (Figure 2-12a), similar to that of the 
CID-Trf4 NIM complex (60, 61). In comparison, the Kd for the Y2058F mutant of NIM2 was 30-
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fold higher, confirming the importance of the hydroxyl group of the Y0 residue for CID binding. 
Similarly, mutation of the Y-2 residue, D2056N, led to a 13-fold increase in the Kd, while 
mutations of the Y+2 residue, P2060A, and P2060V, led to around 20-fold increase in the Kd 
(Figure 2-12b).  
Mutations in the NIM binding site of Nrd1 CID were introduced and their effects on the 
interaction were characterized using fluorescence anisotropy assays. The Y67A mutant showed a 
90-fold increase in the Kd for NIM2, and the D70A mutant had a 30-fold increase (Figure 2-12c). 
In comparison, the D70N mutant showed only 3-fold higher Kd, indicating that the charge on this 
residue is not essential for NIM binding.  
The Kd of the CID-NIM1 complex was 4-fold higher than that of the NIM2 complex, while 
the Kd of the CID-NIM3 complex was 20-fold higher (Figure 2-12d). The Kd of the Mpp6 peptide, 
which also has a Leu at the Y+2 position (Figure 2-4d), is 13.6 µM (61). Together with the data 
on the P2060A and P2060V mutants, observations from the fluorescence anisotropy assays 
suggested that several hydrophobic residues could be tolerated at the Y+2 position. In comparison, 
the Pol II Ser5P CTD peptide had the weakest affinity for the CID, with a Kd of 216±56 µM, which 
is comparable to the value reported previously (60). This could possibly result from the 
substantially different binding mode of the CTD peptide to the NIMs (Figure 2-9d) or the lack of 





Figure 2-12. Binding affinity between Nrd1 CID and Sen1 NIMs. (a) Fluorescence anisotropy binding 
data for wild-type NIM2 and the Y2058F mutant. The observed Kd values are indicated. (b) Fluorescence 
anisotropy competition binding data for wild-type NIM2 and three mutants. (c) Fluorescence anisotropy 
binding data for NIM2 with wild-type and mutant CID. (d) Fluorescence anisotropy competition binding 
data for NIM1, NIM2, NIM3, and the Pol II Ser5P CTD. Error bars represent standard deviations from 
triplicate measurements.   
 
2.3.6 Biochemical studies of the interaction between Nrd1, Nab3, and Sen1 
Pull-down assays showed that mutations of the Y0 Tyr residues in all three NIMs in Sen1 
CTS (Y1887A, Y2058A, Y2186A) were able to abolish the interaction with CID, while single-site 
mutants were still able to interact with CID (Figure 2-13). Mixing assays also confirmed that other 
regions of Sen1, such as its helicase or HEAT repeat domain, could not interact with Nrd1 CID. 
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Moreover, Nrd1 lacking the CID could not mediate the formation of the NNS complex (Figure 2-
14). Overall, these data indicate that, under the conditions tested here, Sen1 interacts with Nrd1 
solely through the NIM-CID contacts, and that Sen1 does not interact with Nab3.  
 
 
Figure 2-13. Mutations of all three NIMs block the Sen1-Nrd1 interactions. His-tagged wild-type and 
mutant Sen1 (1881-2231) proteins were co-expressed with untagged Nrd1 CID. Single mutants of the Sen1 






Figure 2-14. Sen1 interacts with Nrd1 only through the CID. Mixtures of purified Sen1, Nrd1, and Nab3 
proteins were run on a size-exclusion chromatography column, and the indicated fractions were resolved 
by SDS-PAGE. (a) No interaction between Sen1 HEAT repeat domain and Nrd1 CID. (b) No interaction 
between the Sen1 helicase domain and CID. (c) No ternary complex among full-length Nab3, Sen1 HEAT 
repeat domain, and Nrd1 lacking the CID. (d) No ternary complex among full-length Nab3, Sen1 helicase 
domain, and Nrd1 lacking the CID. (e) No ternary complex among full-length Nab3, Sen1 CTS, and Nrd1 
lacking the CID. (f) Interaction observed between the helicase domain and CTS of K. lactis Sen1 and the 
CID and DD of K. lactis Nrd1 as the positive control of mixing experiments. 
 
2.3.7 Functional studies of the interactions between Nrd1 and Sen1 
The Sen1-Nrd1 interactions were characterized by our collaborator using in vivo studies in 
S. cerevisiae. Consistent with earlier data (121), deletion of the Sen1 CTS had no obvious effect 
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on growth, nor did mutating the NIM Y0 tyrosine residues to alanine, individually or in 
combination (data not shown). However, although none of the Nrd1 CID interactions are essential 
under laboratory growth conditions, the Nrd1 CID deletion does show NNS termination defects in 
a sensitive reporter assay (122). When the SNR13 terminator is placed in an intron upstream of the 
Cup1 coding region, NNS read-through produces a functional Cup1 mRNA that confers resistance 
to copper in the growth medium. This reporter was used in cells with a chromosomal Sen1 
mutation (E1597K) and tested whether the Sen1 constructs complement the defect (reverting cells 
back to copper sensitivity) or were also defective (copper resistance). Interestingly, the 1-1884 
construct lacking the entire CTS fully complements a SEN1 deletion or the E1597K point mutant 
for overall growth rate, but is not effective at preventing NNS readthrough at the reporter (Figure 
2-15a). In contrast, the smaller deletions that retain one (1-2055) or two (1-2183) NIMs completely 
restore termination and copper sensitivity. A NIM1 point mutant in the context of the 1-2055 
construct apparently terminates effectively on this reporter as well, so the function could not be 
definitively assigned to the NIM of Sen1. Nonetheless, the in vivo results suggest that Sen1 region 
1884-2055 containing NIM1 does contribute to Sen1 function. 
On the other hand, removing or mutating NIMs from the Sen1 CTS had a profound effect 
on the interaction with Nrd1, based on co-immunoprecipitation experiments (Figure 2-15b). The 
Sen1 mutant with deletions of all three NIMs showed essentially no binding to Nrd1. A Sen1 
mutant with one NIM showed weaker binding than that with two NIMs, and mutation of the Y0 





Figure 2-15. Characterization of the effects of the Sen1-Nrd1 interaction in yeast. (a) Various C-
terminal truncations of Sen1 were transformed into SEN1 wild-type or E1597K point mutant cells and 
tested for the ability to prevent NNS readthrough at the Cup1 reporter. NNS termination defects result in 
copper resistance. The 1-1884 construct of Sen1, which lacks all three NIMs, could not prevent readthrough. 
(b) Cell extracts from the indicated Sen1 strains were immunoprecipitated with anti-Sen1 antibody and 
probed for the presence of Nrd1 and Sen1 proteins. The NIMs present in each protein are listed below each 
lane. Positions of Sen1 proteins are marked with a single asterisk, the dark band marked with two asterisks 
is the IgG heavy chain. 
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As reported previously (97, 113), normal levels of full-length Sen1 are extremely low and 
difficult to detect by Western blotting. As a result, correspondingly little Nrd1 was detected upon 
immunoprecipitation (Figure 2-15b). Certain N-terminal truncations stabilize Sen1 by removing 
degradation-promoting sequences (113, 123). Similarly, the C-terminal truncation of Sen1 also 
showed higher expression levels of Sen1, suggesting additional degradation signals in the CTS.  
The Nrd1 CID now has four known binding partners, Sen1, Trf4 (60), Mpp6 (61) and Pol 
II CTD (57, 58), and other motifs that bind this CID could also be possible. Further studies will 
shed light on whether additional motifs could actually mediate interactions between Nrd1 CID and 
other proteins, and how the Sen1-Nrd1 interactions mediate the functions of the Nrd1-Nab3-Sen1 
complex.  
 
2.4 Conclusions and future directions 
Three Nrd1-interacting motifs (NIMs) in the CTS of S. cerevisiae Sen1 were identified, 
and the crystal structures of the S. cerevisiae Nrd1 CID in complex with the three Sen1 NIM 
peptides were determined, which elucidated the molecular basis for their recognition by Nrd1 CID. 
Although the Sen1 NIMs is not essential for supporting viability from the in vivo studies conducted 
by our collaborator, termination defects were observed from NIM deletions in a reporter assay. In 
addition, the conservation of these regions suggests these interactions are very likely to promote 
NNS function. Therefore, future functional studies, such as termination assays of the wild-type 
and mutant Nrd1 could provide more information regarding the importance of the Nrd1-Sen1 
interactions in the transcription termination process of non-coding RNAs. In addition, although 
the deletion of the Sen1 CTS did not affect the growth of S. cerevisiae, it could still have effects 
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on the cells under more stringent conditions, so more experiments are needed to test the effects of 
the deletion on the growth under various stress conditions. 
Furthermore, yeast cell lines could be used for the recombinant expression of full-length 
Sen1, which is a protein of more than 2,000 residues. If the full-length Sen1 could be expressed 
and purified, future structural studies could be conducted on the protein using electron microscopy. 
In addition, if the full-length Sen1 could be assembled with Nrd1 and Nab3 to reconstitute the full-
length NNS complex, the N-terminal HEAT repeat domain of Sen1 could potentially contribute to 
the overall stability of the complex and increase the significance of the structural and functional 
















Structural studies of the SPOC domain of FPA in plants 
 
3.1 Introduction 
When eukaryotic DNA is transcribed into messenger RNAs (mRNAs) through 
transcription by RNA polymerase II (Pol II), the nascent transcript undergoes extensive processing 
including 3’-end cleavage and polyadenylation to become mature mRNA (124-127). In addition, 
most genes have multiple 3’-end polyadenylation sites, which leads to alternative 3’-end cleavage 
and polyadenylation (128, 129). As an essential and ubiquitous process in eukaryotes, 
misregulation of alternative 3’-end processing will lead to various genetic diseases and cancer (130, 
131). As a result, the functional mechanism of this process is of general interest, since it could 
contribute greatly to the development of new therapeutic approaches. In the last decade, the major 
factors involved in this process have been identified, but most of their functions and mechanisms 
are still unknown. 
The split ends (SPEN) family of proteins was identified as RNA binding proteins that 
regulate alternative 3¢-end cleavage and polyadenylation (132). They are characterized by 
possessing N-terminal RNA recognition motifs (RRMs) and a conserved SPEN paralog and 
ortholog C-terminal (SPOC) domain (133, 134) (Figure 3-1). As a protein-protein interaction 
domain, the SPOC domain has diverse functions among SPEN family proteins (135), but the 
mechanism of these functions remain to be discovered. In human, there are 3 SPEN family proteins: 
RNA-Binding Motif protein 15 (RBM15), RNA-Binding Motif protein 15B (RBM15B), and 
SMRT/HDAC1 Associated Repressor Protein (SHARP). The first two are involved in 
transcription repression through H3K4 trimethylation on target locus, which requires the 
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interaction between the SPOC domain and their binding partners to recruit the H3K4 methylase 
(136). However, the exact mechanism of these interactions is still unknown. Also, these two 
proteins are mutated in various cancer types, implying that they are tumor suppressors (132). As a 
result, the molecular interactions of SPOC domain are of general interest, as it could offer insights 
into the development of cancer therapy. 
 
 
Figure 3-1. Domain organization of A. thaliana FPA. The domains are given different colors, RRM 
(green), SPOC domain (yellow). The start and end of the protein and the SPOC domain are labeled with 
residue numbers. 
 
FPA, a SPEN family protein in Arabidopsis thaliana and other plants, regulates the 3¢-end 
alternative cleavage and polyadenylation of the antisense RNAs of FLOWERING LOCUS C (FLC), 
a flowering repressor gene (137-139). FPA associates directly with the FLC locus to promotes the 
3¢-end processing of class I FLC antisense RNAs, which includes the proximal polyadenylation 
site (138). However, the functional mechanism of this complex is still obscure.  
Although SPOC domain is a conserved domain shared among the SPEN family proteins, 
its sequence conservation is surprisingly low. For example, the sequence identity between the 
SPOC domains of A. thaliana FPA and human SHARP is only 19% (Figure 3-2). The SHARP 





Figure 3-2. Sequence alignment of the SPOC domains of Arabidopsis thaliana FPA, human RBM15, 
Drosophila SPEN, mouse MINT, and human SHARP. The secondary structure elements in the structure 
of FPA SPOC and SHARP SPOC are labeled. Residues that are strictly conserved among the five proteins 
are shown in white with a red background and those that are mostly conserved in red. This figure was 
generated from ESpript (http://espript.ibcp.fr) (141). 
 
Pcf11p-similar protein 2 (PCFS2), an Arabidopsis homolog of the 3’-end processing factor 
Pcf11 in yeast and human, was identified by our collaborator Gordon Simpson at Dundee 
University as the immediate protein partner of FPA. The interaction of PCFS2 with the SPOC 
domain of FPA at the FLC 3’-end locus was discovered and confirmed by in vivo formaldehyde 
cross-linking, mass spectrometry, and yeast two-hybrid assay (unpublished data). Therefore, the 
structural information of the FPA SPOC domain in complex with PCFS2 could shed light on the 
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functional mechanism of the FPA-PCFS2 complex in alternative 3’-end cleavage and 
polyadenylation of class I FLC antisense RNAs. 
In order to understand the molecular basis of the regulation of alternative 3¢-end processing 
of FLC antisense by FPA, we determined the crystal structure of the SPOC domain of A. thaliana 
FPA at 2.7 Å resolution (142). The overall structure shows resemblance to that of the SHARP 
SPOC domain, though substantial conformational differences are also observed between them. 
The structure reveals a surface patch that is conserved among FPA homologs, which could 
potentially be the interaction interface with PCFS2. Functional and biochemical studies were also 
performed to characterize the interactions between FPA and its interacting partners. 
 
3.2 Experimental procedures 
3.2.1 Protein expression and purification 
The SPOC domain (residue 433-565) of Arabidopsis thaliana FPA was sub-cloned into the 
pET28a vector (Novagen). The recombinant protein, with an N-terminal hexahistidine tag, was 
over-expressed in E. coli BL21 Star (DE3) cells (Novagen), which were induced with 0.4 mM 
IPTG and allowed to grow at 20 °C for 14–18 h. The soluble protein was purified by nickel-
charged immobilized-metal affinity chromatography and size-exclusion chromatography. The 
purified protein was concentrated and stored at –80 °C in a buffer containing 20 mM Tris (pH 8.0), 
200 mM NaCl, 10 mM DTT and 5% (v/v) glycerol. The His-tag was not removed for 
crystallization.  
The selenomethionine labeled SPOC domain was expressed in E. coli B834(DE3) strain 




3.2.2 Protein crystallization 
Crystals of the native SPOC domain of FPA were grown at 20 °C with the sitting-drop 
vapor diffusion method. The protein solution was at 30 mg/ml concentration, and the reservoir 
solution contained 0.2 M MgSO4, and 20% (w/v) PEG 3350. Fully-grown crystals were obtained 
two days after set-up. Crystals of the selenomethionine labeled SPOC domain were grown using 
the same condition as the native protein. The crystals were cryoprotected in the crystallization 
solution supplemented with 20% (v/v) glycerol and flash-frozen in liquid nitrogen for data 
collection at 100K. 
 
3.2.3 Data collection and processing 
A single-wavelength anomalous dispersion (SAD) X-ray diffraction data set on a 
selenomethionine-labeled SPOC domain crystal was collected at the National Synchrotron Light 
Source (NSLS) beamline X29A using an ADSC Q315r CCD. The diffraction images were 
processed and scaled with the HKL package (144). The crystal belongs to space group P65, with 
unit cell parameters of a = b = 108.2 Å, and c = 34.2 Å. 
 
3.2.4 Structure determination and refinement 
The structure of the SPOC domain was solved by the selenomethionyl SAD method (145) 
with the program SHELX (146). The phases were used by program PHENIX (118) for automatic 
model building. Manual model rebuilding was carried out with Coot (119). The structure 
refinement was performed with the program PHENIX, with translation, libration, and screw-
rotation (TLS) parameters. The data processing and refinement statistics are summarized in Table 
3-1. The Ramachandran plot showed that 96.6% of the residues are located in the most favored 
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regions, and 3.4% are in additional allowed regions. The structure has been deposited in the Protein 
Data Bank, with accession code 5KXF.  
 
Table 3-1. Summary of crystallographic information 
Data collection  
Space group P65 
Cell dimensions  
a, b, c (Å) 108.2, 108.2, 34.2 
a, b, g (°) 90, 90, 120 
Resolution range (Å)1 50-2.7 (2.8-2.7) 
No. of observations 78,008 
No. of unique reflections 6,505 
Rmerge (%) 10.5 (45.3) 
I/sI 24.1 (6.3) 
CC1/2 0.999 (0.949) 
Completeness (%) 100 (100) 
Redundancy 12.0 
Refinement  
Resolution range (Å) 50-2.7 (2.8-2.7) 
No. of reflections 6,490 
Rwork (%) 19.2 (25.0) 
Rfree (%) 25.4 (35.4) 






RMS deviations  
Bond lengths (Å) 0.017 
Bond angles (°) 1.9 
Ramachandran plot statistics (%)  
Most favored region 96.6 
Additional allowed region 3.4 




3.2.5 Mixing assay 
Mixtures of purified proteins were incubated on ice for 1 h and ran on Superose 12 Increase 
10/300 GL column (GE Healthcare) in 20 mM Tris (pH 8.0), 200 mM NaCl, 10 mM DTT.  
 
3.2.6 Pull-down assay 
Regions of A. thaliana PCFS2 was sub-cloned into the pET26b vector (Novagen). The 
recombinant PCFS2 proteins would contain a C-terminal hexahistidine tag. The plasmid was co-
transformed with one for un-tagged A. thaliana FPA SPOC domain (residues 433-565) and over-
expressed in E. coli BL21 Star (DE3) cells (Novagen). The culture was induced with 0.4 mM IPTG 
and allowed to grow at 16 °C for 16–20 h. The soluble protein was incubated with nickel-charged 
resin for 1 h at 4 °C, washed with a buffer containing 20 mM Tris (pH 8.0), 200 mM NaCl, 20 mM 
imidazole and eluted with a buffer containing 20 mM Tris (pH 8.0), 200 mM NaCl, 150 mM 
imidazole. The eluate was mixed with protein dye and run on an SDS-PAGE gel. 
 
3.3 Results and discussions 
3.3.1 Construct design and protein expression 
Previous studies have shown the SPOC domain of A. thaliana FPA is approximately 
located at residue 441-561 (133, 134) (Figure 3-1). In addition, based on the secondary structure 
prediction and sequence alignment of the SPOC domains of 5 SPEN proteins (A. thaliana FPA, 
human RBM15, Drosophila SPEN, mouse MINT, and human SHARP) (Figure 3-2), five 
constructs were sub-cloned in pET19b or pET28a vectors with N-terminal His-tags for protein 
expression in E. coli (Table 3-2). Since all five constructs showed a high level of expression and 
58 
 
solubility from small-scale expression tests in E. coli, these proteins were purified from large-scale 
E. coli culture using Ni-NTA affinity chromatography followed by Sephacryl S-300 size-exclusion 
chromatography (Figure 3-3). The resulting proteins were pure and homogeneous, based on the 
SDS-PAGE gel and the size-exclusion chromatography profile (Figure 3-3), which were 
concentrated to 30 mg/ml for crystallization screens. 
 
Table 3-2. Summary of constructs of A. thaliana FPA SPOC domain 
Name Tag Vector Start End Total Residue 
M.W. 





SPOC N-His pET19b 441 589 149 16,572 6.2 0.89 3 3 
SPOC-2 N-His pET28a 433 565 133 14,615 5.7 0.80 3 3 
SPOC-4 N-His pET28a 433 576 144 15,834 5.7 0.83 3 3 
SPOC-6 N-His pET28a 441 565 125 13,797 6.8 0.85 3 3 




Figure 3-3. Size-exclusion chromatography of A. thaliana FPA SPOC domain (433-565). The eluted 
fractions were monitored using absorbance at 280nm and analyzed by SDS-PAGE. S: soluble fraction of 
lysate, E: Ni-NTA eluate. 
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3.3.2 Crystal screening and optimization 
 The purified A. thaliana FPA SPOC domain samples were screened for crystallization 
conditions from four commercial crystallization suites by sitting drop vapor diffusion at 20 °C. 
Crystals were observed from the FPA SPOC domain construct containing residue 433-565 in two 
crystallization conditions. Cube-shaped crystals appeared after two days in a condition containing 
0.1M citric acid (pH 3.5) and 3M sodium chloride (Figure 3-4a). In addition, rod-shaped crystals 
appeared after two days in a condition containing 0.2 M MgSO4 and 20% (v/v) PEG 3350 (Figure 
3-4b). After several rounds of optimization, the crystals from both conditions diffracted to around 
4 Å using an in-house X-ray source. 
 
 
Figure 3-4. Crystals of A. thaliana FPA SPOC domain (433-565) from two conditions. (a) Cube-shaped 
crystals from 0.1M citric acid (pH 3.5) and 3M sodium chloride. (b) Rod-shaped crystals from 0.2 M 




3.3.3 Selenomethionine labeling for phase determination 
As the A. thaliana FPA SPOC domain does not share high sequence identity with any 
existing protein crystal structure, crystals of the selenomethionine-labeled protein are needed for 
structure determination using the single-wavelength anomalous diffraction (SAD) method (145). 
As a result, selenomethionine-labeled FPA SPOC domain construct containing residue 433-565 
was expressed and purified for crystallization.  
Surprisingly, no crystal was observed from the condition containing 0.1M citric acid (pH 
3.5) and 3M sodium chloride, which could possibly be caused by the bulky selenomethionine 
disrupting the crystal packing of the native protein crystals. Nonetheless, selenomethionine-
labeled FPA SPOC domain (433-565) still crystallized in the condition containing 0.2 M MgSO4 
and 20% (v/v) PEG 3350, and the optimized crystals were used for structure determination. 
 
3.3.4 Structure determination and characterization 
The crystal structure of the SPOC domain of A. thaliana FPA has been determined at 2.7 
Å resolution using the selenomethionyl single-wavelength anomalous diffraction (SAD) method. 
The expression construct contained residues 433-565 of FPA, but the density of residues 433-438 
and 461-464 are not observed in the crystal, possibly due to their flexibility. The atomic model has 
good agreement with the X-ray diffraction data and the expected bond lengths, bond angles and 
other geometric parameters (Table 3-1). All the residues are located in the favored regions of the 
Ramachandran plot.  
The crystal structure of the FPA SPOC domain consists of a b-barrel, which contains seven 
strands (b1-b7) that are mostly anti-parallel, and three helices (aA-aC) (Figure 3-5a). b1 and b3 
are the only two neighboring strands parallel to each other. Helix aB covers one end of the barrel, 
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while the loop connecting strands b2 and b3, which contains the disordered 461-464 segment, 
covers the other end of the b-barrel. Helices aA and aC are located next to each other at one side 
of the barrel (Figure 3-5b). The center of the barrel is filled with hydrophobic side chains and is 
not accessible to the solvent.  
 
 
Figure 3-5. Crystal structure of A. thaliana FPA SPOC domain (433-565). (a) Schematic drawing of 
the structure of FPA SPOC domain, colored from blue at the N terminus to red at the C terminus. The view 
is from the side of the b-barrel. The disordered segment (residues 460-465) is indicated with the dotted line. 
(b) Structure of the FPA SPOC domain, viewed from the end of the b-barrel, after 90° rotation around the 
horizontal axis from (a).  
 
3.3.5 Comparisons to structural homologs of the SPOC domain 
A search for structural homologs of the FPA SPOC domain with the DaliLite server (147) 
resulted in only five hits from the Protein Data Bank, which suggests that the SPOC domain is 
rather unique structurally. The hit with the highest similarity is the SPOC domain of human 
SHARP (135, 140) with a Z score of 12.3(Figure 3-6a). The other four structural homologs include 
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the b-barrel domain of the proteins Ku70 and Ku80 (Z score 11.4) (148) (Figure 3-6b), a domain 
in the chromodomain protein Chp1 (Z score 10.8) (149) (Figure 3-5c), and the activator interacting 
domain (ACID) of the Med25 subunit of the Mediator complex (Z score 8.5) (150-153) (Figure 3-
6d). The next structural homolog has a Z score of 3.0.  
 
 
Figure 3-6. Structural homologs of the FPA SPOC domain. (a) Overlay of the structures of the FPA 
SPOC domain (cyan) and the SHARP SPOC domain (gray). The bound position of a doubly-
phosphorylated peptide from SMRT is shown in magenta. (b) Overlay of the structures of the FPA SPOC 
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domain (cyan) and the Ku70 b-barrel domain (gray). Ku80 contains a homologous domain (green), which 
forms a heterodimer with that in Ku70. The two domains and inserted segments on them mediate the binding 
of dsDNA (orange). The red rectangle highlights the region of contact between the two b-barrel domains. 
(c) Overlay of the structures of the FPA SPOC domain (cyan) and the homologous domain in Chp1 (gray). 
The binding partner of Chp1, Tas3, is shown in green. The red rectangle indicates the region equivalent to 
the binding site of the SMART phosphopeptide in SHARP SPOC domain, where a loop of Tas3 is also 
located. (d) Overlay of the structures of the FPA SPOC domain (cyan) and the Med25 ACID (gray). 
 
SHARP is a transcriptional co-repressor in the nuclear receptor and Notch/RBP-Jk 
signaling pathways (154, 155). SHARP interacts directly with silencing mediator for retinoid and 
thyroid receptor (SMRT), nuclear receptor co-repressor (N-CoR), HDAC, and other components 
through The SPOC domain for transcriptional repression. While the overall structure of the SPOC 
domain of FPA is similar to that of SHARP, b-strands and the helices are positioned differently, 
and most of the loops also show substantially different conformations (Figure 3-6a). Furthermore, 
a doubly-phosphorylated peptide from SMRT is bound to the side of the barrel, near strands b1 
and b3 (135) (Figure 3-6a). However, the peptide would clash with the b1-b2 loop under this 
binding mode in FPA.  
The Ku70-Ku80 heterodimer is involved in DNA double-strand break repair, and the b-
barrel domains are specifically for DNA binding (148). In fact, the b-barrel domains of Ku70 and 
Ku80 form a heterodimer through the loops between the third and fourth strands of the barrel 
(Figure 3-6b). The open ends of the two b-barrels face the DNA binding sites, and contact the 
phosphodiester backbone of the dsDNA. In addition, a long insert connecting strands b2 and b3 in 
the two domains form an arch-like structure, encircling the dsDNA.  
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Chp1 is a subunit of the RNA-induced initiation of transcriptional gene silencing (RITS) 
complex (149). Tas3, the binding partner of Chp1, is bound between the b-barrel domain and the 
second domain of Chp1 (Figure 3-6c). The linker between the two domains is important for this 
interaction, as the b-barrel itself is possibly not sufficient to bind Tas3. Interestingly, Tas3 contacts 
strand b3 of the barrel domain through a loop, which shows a similar binding mode as the N-
terminal segment of the SMRT peptide with SHARP SPOC domain (Figure 3-6a).  
Med25, a subunit of the coactivator complex Mediator that promotes transcription by Pol 
II, is the target of the potent activator VP16 of the herpes simplex virus through its activator 
interacting domain (ACID) (150-153). The structure of ACID contains a helix at the C-terminus 
as well as an extended b1-b2 loop (Figure 3-6d). Nonetheless, the binding site for VP16 has been 
mapped to roughly the same surface patch, near strands b1 and b3, that is used by the SHARP and 
Tas3 SPOC domains for binding their partners.   
 
3.3.6 A conserved surface patch in the FPA SPOC domain 
A large surface patch near strands b1, b3, b5 and b6 of the SPOC domain is conserved 
among plant FPA homologs, both on a structural level and a sequence level (Figure 3-7a) (156). 
This surface patch consists of two sub-patches: the first one formed by Lys447 (in strand b1), 
Arg477 (b3), Tyr515 (aB) and Arg521 (b5), and the second one formed by His486 (aA), Thr478 
(b3), Val524 (b5) and Phe534 (b6) (Figure 3-7b). The first surface patch is electropositive in 
nature (Figure 3-7c), and residues Arg477 and Tyr515 are also conserved in the SHARP SPOC 
domain (Figure 3-2). Actually, this surface patch of SHARP SPOC domain interacts with one of 
the phosphorylated residues of the SMRT peptide (Figure 3-6a), which suggests that this surface 
65 
 
patch of the FPA SPOC domain could potentially interact with a phosphorylated segment. In 
comparison, the second surface patch is more hydrophobic in nature (Figure 3-7c). 
 
 
Figure 3-7. A conserved surface patch of FPA SPOC domain. (a) Two views of the molecular surface 
of FPA SPOC domain colored based on sequence conservation among plant FPA homologs. The color 
scheme is also indicated. Purple: most conserved; cyan: least conserved. (b) Residues in the conserved 
surface patch of FPA SPOC domain. The side chains of the residues are shown in stick models, colored 
orange in the first sub-patch and green in the second. (c) Molecular surface of FPA SPOC domain colored 




3.3.7 Functional studies of FPA-SPOC 
Based on the obtained structural information, the potential impact of the conserved surface 
patches on FPA function in vivo was examined by our collaborator. Arg477 and Tyr515 from the 
first surface patch, which are conserved in the SHARP SPOC domain (Figure 3-2) and functionally 
important (140), were mutated. The mutations were introduced into a transgene designed to 
express FPA from its native control elements (promoter, introns, and 3¢ UTR). The resulting 
transgenes were then stably transformed into a pre-terminated fpa-8 mutant background so that the 
impact of the mutations on FPA function could be assessed. Control transformation of the same 
expression constructs into fpa-8 would express wild-type FPA protein (Figure 3-8a) and restore 
FPA protein expression to near wild-type levels to rescue the function of FPA in controlling RNA 
3¢-end formation. Transgenic lines expressing either the R477A or Y515A mutation were 
examined separately, and protein expression was restored close to wild-type levels in protein blot 
analyses using antibodies that specifically recognize FPA (Figure 3-8b). 
Then, the impact of the surface patch mutations on FPA’s function in controlling RNA 3¢-
end formation was examined by determining whether the mutant proteins functioned in the 
repression of FLC expression (137). The expression of FLC mRNA was measured by RT-qPCR 
and the elevated levels of FLC detected in fpa-8 mutants were restored to near wild-type levels in 





Figure 3-8. The protein and RNA levels of FPA. (a) FPA protein level in FPA::FPAwt fpa-8 plants. 
Proteins isolated from wild type Col-0, fpa-8, 35S::FPA:YFP and independent FPA::FPAwt transgenic 
lines were separated on 8% SDS-PAGE. Western blot analysis was performed with FPA antibody (138). 
TUBULIN was detected as a control. (b). RNA gel blot analysis of WT A. thaliana accession Columbia 
(Col-0) plants fpa-8 and fpa-8 mutants expressing FPA::FPAwt using poly(A)+ purified mRNAs. A probe 
corresponding to the 5¢UTR region of FPA mRNA was used to detect FPA specific mRNAs. RNA size (kb) 
marker (Ambion). TUBULIN was detected as an internal control. Proximally and distally polyadenylated 







Figure 3-9. Impact of individual FPA SPOC domain mutations on FLC transcript levels. The RT-
qPCR analysis was performed with total RNA purified from Col-0, fpa-8, 35S::FPA:YFP, FPA::FPA 
R477A (a), and FPA::FPA Y515A (b) plants. Transcript levels were normalized to the control UBC. 
Histograms show mean values ±SE for three independent PCR amplification of three biological replicates.   
 
FPA autoregulates its expression by promoting cleavage and polyadenylation within intron 
1 of its own pre-mRNA, resulting in a truncated transcript that does not encode a functional protein 
(138). As a result, the impact of the surface patch mutations on FPA autoregulation was examined. 
RNA gel blot analyses revealed that for every mutant, in each of three independent transgenic lines, 






Figure 3-10. Impact of individual FPA SPOC domain mutations on alternative polyadenylation of 
FPA pre-mRNA. RNA gel blot analysis of WT A. thaliana accession Columbia (Col-0) plants fpa-8 and 
fpa-8 mutants expressing either FPA::FPA R477A (a) or FPA::FPA Y515A (b) using poly(A)+ purified 
mRNAs. A probe corresponding to the 5’UTR region of FPA mRNA was used to detect FPA specific 
mRNAs. RNA size (kb) marker (Ambion). TUBULIN was detected as an internal control. Proximally and 
distally polyadenylated FPA transcripts are marked with arrows. The ratio of distal:proximal 
polyadenylated forms is given under each lane. 
 
Since each surface patch mutation appeared to be insufficient to disrupt FPA functions on 
its own, both mutations were combined into the same transgene. Again, near wild-type levels of 
FPA protein were expressed from three independent transgenic lines with R477A/Y515A double 
mutation in an fpa-8 mutant background (Figure 3-11a). However, R477A/Y515A mutant FPA 
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functioned like wild-type FPA and restored FPA pre-mRNA proximal polyadenylation (Figure 3-
11b) and FLC expression to wild-type levels (Figure 3-11c).  
 
 
Figure 3-11. Impact of FPA SPOC domain double mutations on alternative polyadenylation of FPA 
pre-mRNA and FLC expression. (a) RNA gel blot analysis of FLC transcript in FPA::FPAwt plants.  
Poly(A)+ RNA was isolated from Col-0, fpa-8 and transgenic lines expressing FPA::FPAwt in an fpa-8 
mutant background and detected with a probe recognizing FLC sequence. TUBULIN was detected as a 
control. (b) RNA gel blot analysis of WT A. thaliana accession Columbia (Col-0) plants fpa-8 and fpa-8 
71 
 
mutants expressing FPA::FPA R477A;Y515A using poly(A)+ purified mRNAs. Black arrows indicate the 
proximally and distally polyadenylated FPA mRNAs. A probe corresponding to the 5’UTR region of FPA 
mRNA was used to detect FPA specific mRNAs. RNA size (kb) marker (Ambion). TUBULIN was detected 
as an internal control. The ratio of distal:proximal polyadenylated forms is given under each lane.  (c) the 
RT-qPCR analysis was performed with total RNA purified from Col-0, fpa-8, and FPA::FPA 
R477A;Y515A plants. Transcript levels were normalized to the control UBC. Histograms show mean 
values ±SE for three independent PCR amplification of three biological replicates.   
 
According to the functional studies in vivo, either the SPOC domain is not required for the 
role of FPA in regulating RNA 3¢-end formation, or that this combination of mutations is not 
sufficient to critically disrupt the function of the FPA SPOC domain. Since the corresponding 
mutations in the SHARP SPOC domain do disrupt its recognition of unphosphorylated SMRT 
peptides (135), these observations may reinforce the idea that the features and functions of the 
FPA SPOC domain differ from those of the only other well-characterized SPOC domain. 
 
3.3.8 Biochemical studies of FPA-SPOC and PCFS2 
The immediate protein partner of FPA at the FLC 3’-end locus was identified by our 
collaborator using in vivo formaldehyde cross-linking and mass spectrometry. Pcf11p-similar 
protein 2 (PCFS2), an Arabidopsis thaliana homolog of the 3’-end processing factor Pcf11 in yeast 
and human, has been pulled down by the assay, indicating its interaction with FPA during the 
alternative cleavage and polyadenylation of the FLC antisense. Using yeast two-hybrid assay, they 
discovered that the SPOC domain of FPA interacts with the segment containing residues 595-759 






Figure 3-12. Domain organization of A. thaliana PCFS2. The domains are given different colors, CID 
(red), Zinc-finger motif (yellow), and CLP1-interacting domain (blue). The start and end of each domain 
are labeled with residue numbers. 
 
Therefore, various constructs of PCFS2, including regions between the start of the N-
terminal CTD-interacting domain (CID) domain to the end of the SPOC-interacting region, were 
sub-cloned in pET28a or pET26b vectors with N-terminal or C-terminal His-tags for protein 
expression in E. coli (Table 3-3). Most of the constructs showed minimal to no expression from 
the small-scale expression tests in E. coli, but the C-terminal tagged constructs of PCFS2(237-753) 
and PCFS2(77-753) showed some expression from small-scale expression tests in E. coli. 
Therefore, these two constructs were used for attempts to purify a complex of PCFS2 and FPA 
SPOC domain. However, no complex was formed from either pull-down assay after co-expression 









Table 3-3. Summary of constructs of A. thaliana PCFS2  
Name Tag Vector Start End Total Residue 
M.W. 





PCFS2-1 N-His pET28a 501 759 777 26,661 8.2 0.01 0 0 
PCFS2-2 C-His pET26b 501 759 777 26,661 8.2 0.01 0 0 
PCFS2-3 N-His pET28a 599 863 795 28,027 7.8 0.41 0 0 
PCFS2-4 C-His pET26b 599 863 795 28,027 7.8 0.41 0 0 
PCFS2-5 N-His pET28a 599 813 645 22,135 6.1 0.01 1 1 
PCFS2-6 C-His pET26b 599 813 645 22,135 6.1 0.01 0 0 
PCFS2-7 N-His pET28a 669 863 585 20,897 9.0 0.54 0 0 
PCFS2-8 C-His pET26b 669 863 585 20,897 9.0 0.54 1 1 
PCFS2-9 N-His pET28a 669 813 435 15,005 8.6 0.01 0 0 
PCFS2-10 C-His pET26b 669 813 435 15,005 8.6 0.01 0 0 
PCFS2-11 N-His pET28a 753 863 333 12,346 9.0 0.90 0 0 
PCFS2-12 C-His pET26b 753 863 333 12,346 9.0 0.90 0 0 
PCFS2-13 N-His pET28a 599 753 465 15,770 5.6 0.01 0 0 
PCFS2-14 C-His pET26b 599 753 465 15,770 5.6 0.01 0 0 
PCFS2-41 N-His pET28a 237 753 517 56,151 6.2 0.702 0 0 
PCFS2-42 C-His pET26b 237 753 517 56,151 6.2 0.702 1 1 
PCFS2-43 N-His pET28a 77 753 677 74,020 6.9 0.748 0 0 




Figure 3-13. Pull-down assay and mixing assay of A. thaliana PCFS2 and FPA SPOC domain. (a) His-
tagged PCFS2 (77-753) was co-expressed with untagged FPA SPOC domain (433-565) in E. coli. P: pellet, 
FT: flow through, W: wash, E: Ni column eluate. (b) Mixtures of purified PCFS2 (77-753) and FPA SPOC 
domain (433-565) were run on a size-exclusion chromatography column, and the indicated fractions were 




Although no interaction was observed between A. thaliana PCFS2 and FPA SPOC domain, 
it is possible that the SPOC-interacting region spans beyond residue 759 and includes the Zinc-
finger motif (Figure 3-12). Therefore, additional constructs of PCFS2, which includes regions 
between the start of the CID domain and the C-terminus, were sub-cloned (Table 3-4). From the 
small-scale expression tests in E. coli, only the constructs that end at residue 947 showed 
reasonable expression and solubility levels.  
A. thaliana PCFS2 harbors a CLP1-interacting domain within its Zinc-finger domain at its 
C-terminus. As mentioned earlier, A. thaliana PCFS2 is homologous to S. cerevisiae Pcf11 which 
interacts with CLP1 through its CLP1-interacting domain. It is possible that S. cerevisiae CLP1 
bridged the interaction between PCFS2 and FPA SPOC domain in the yeast two-hybrid experiment. 
CLPS3 is the homolog of S. cerevisiae CLP1 in A. thaliana, and the predicted secondary structure 
of CLPS3 is highly similar to that of CLP1. Moreover, the residues at the interaction interface with 
Pcf11 are conserved among the two proteins (Figure 3-14), suggesting that CLPS3 could 
potentially mediate the interaction between PCFS2 and FPA SPOC domain.  
As a result, PCFS2 (237-947), FPA SPOC domain (433-565), and full-length CLPS3 
proteins were used for mixing assays. However, although PCFS2 and CLPS3 formed a complex 
on size-exclusion chromatography, the SPOC domain of FPA did not form a complex with the 







Table 3-4. Summary of additional constructs of A. thaliana PCFS2  
Name Tag Vector Start End Total Residue 
M.W. 





PCFS2-45 N-His pET28a 77 863 787 86,277 8.0 0.77 0 0 
PCFS2-46 C-His pET26b 77 863 787 86,277 8.0 0.77 0 0 
PCFS2-47 N-His pET28a 237 863 627 68,408 7.0 0.74 0 0 
PCFS2-48 C-His pET26b 237 863 627 68,408 7.0 0.74 0 0 
PCFS2-49 N-His pET28a 501 863 363 38,731 9.0 0.28 0 0 
PCFS2-50 C-His pET26b 501 863 363 38,731 9.0 0.28 0 0 
PCFS2-51 N-His pET28a 501 963 463 49,522 5.6 0.42 2 0 
PCFS2-52 C-His pET26b 501 963 463 49,522 5.6 0.42 2 0 
PCFS2-53 N-His pET28a 599 963 365 38,817 5.1 0.54 2 0 
PCFS2-54 C-His pET26b 599 963 365 38,817 5.1 0.54 2 0 
PCFS2-57 N-His pET28a 77 963 887 97,067 6.0 0.79 1 0 
PCFS2-58 C-His pET26b 77 963 887 97,067 6.0 0.79 1 0 
PCFS2-59 N-His pET28a 237 963 727 79,198 5.6 0.76 2 0 
PCFS2-60 C-His pET26b 237 963 727 79,198 5.6 0.76 1 1 
PCFS2-61 N-His pET28a 501 947 447 47,770 5.8 0.44 1 1 
PCFS2-62 C-His pET26b 501 947 447 47,770 5.8 0.44 1 1 
PCFS2-63 N-His pET28a 599 947 349 37,066 5.2 0.57 1 1 
PCFS2-64 C-His pET26b 599 947 349 37,066 5.2 0.57 1 1 
PCFS2-65 N-His pET28a 77 947 871 95,316 6.1 0.80 1 0 
PCFS2-66 C-His pET26b 77 947 871 95,316 6.1 0.80 2 1 
PCFS2-67 N-His pET28a 237 947 711 77,447 5.7 0.78 1 0 







Figure 3-14. Sequence alignment of Saccharomyces cerevisiae CLP1 and Arabidopsis thaliana CLPS3. 
The secondary structure elements of Saccharomyces cerevisiae CLP1 and the predicted secondary structure 
elements of Arabidopsis thaliana CLPS3 are labeled. Residues that are strictly conserved among the two 
proteins are shown in white with a red background and those that are mostly conserved in red. Residues at 
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the interaction interface of CLP1with Pcf11 are indicated with blue arrows, which are mostly conserved 
between the two proteins. This figure was generated from ESpript (http://espript.ibcp.fr) (141). 
 
 
Figure 3-15. Mixing assay of A. thaliana PCFS2, CLPS3, and FPA SPOC domain. Mixtures of purified 
PCFS2 (237-947), CLPS3 (1-443), and FPA SPOC domain (433-565) were run on a size-exclusion 
chromatography column, and the indicated fractions were resolved by SDS-PAGE. 
 
3.4 Conclusions and future directions 
The SPEN family protein FPA in A. thaliana regulates the alternative 3’-end processing of 
FLC class II antisense through the SPOC domain, but the functional mechanism remains to be 
elucidated. The crystal structure of the SPOC domain of A. thaliana FPA was determined at 2.7Å 
resolution, which revealed the molecular basis of the functional difference between FPA and 
another human SPEN family protein SHARP. Potential protein binding sites on the SPOC domain 
were proposed based on its structure and sequence conservation but did not show any functional 
importance in the assays performed.  
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In addition, after various attempts, the interaction between PCFS2 and FPA SPOC domain 
could not be validated in vitro. Future structural, biochemical, and functional studies of the SPOC 
domain, such as mutating other highly conserved residues in vivo or pursuing other identified 
protein binding partners that also function in 3’-end formation, will reveal the binding site and its 
binding protein partners, as well as the functional mechanism of the alternative 3’-end cleavage 
and polyadenylation of FLC class II antisense. Furthermore, the knowledge obtained will not only 
shed light on the mechanism of this process during transcription termination in other eukaryotes, 
but it will also contribute significantly to the development of novel therapeutic approaches to the 
















Structural studies of histone H3 recognition by SETD2 
 
4.1 Introduction 
Post-translational modification (PTM) of histone proteins enforces the regulatory features 
of chromatin during nearly all of the aspects of cellular metabolism, and the modifications include 
phosphorylation, acetylation, and methylation (157). Histone methylations are carried out by 
histone methyltransferases which use S-adenosylmethionine (SAM) to add methyl groups to 
specific histone lysine or arginine residues (158). Methylation of histone lysines plays essential 
roles in every aspect of DNA metabolism such as transcription, DNA replication, recombination, 
and DNA damage repair (159). Among the lysine residues, H3K36 methylation (H3K36me) 
regulates diverse cellular processes and dysregulation of H3K36 methyltransferases is associated 
with many human diseases (160). Interestingly, several of the recently identified oncogenic histone 
mutations are at or near H3K36. For example, H3K36M mutation was discovered in the majority 
of chondroblastoma, H3G34R/V mutations in non-brainstem glioma, and G34W/L mutations in 
giant cell tumors of the bone (161-165). Also, H3K36M transgene dominantly blocks H3K36me 
on wild type histones, while H3G34V or H3G34R transgenes selectively affect H3K36me on the 
mutated histone only (166-169). In addition, mutations that prevent the isomerization of proline 
38 also affect H3K36me (170). However, the regulatory mechanism of these mutations is still 
obscure. 
In fission yeast (Schizosaccharomyces pombe), a single H3K36 methyltransferase Set2 is 
responsible for mono-, di-, and tri-methylation of H3K36 (171, 172). However, multiple H3K36 
methyltransferases are present in mammals, such as NSD1, NSD2/MMSET, NSD3, ASH1L, 
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SETD (Figure 4-1) (160). NSD1, NSD2/MMSET, NSD3, and ASH1L are responsible for 
H3K36me1 and H3K36me2, whereas SETD2 is responsible for H3K36me3 (160, 173-176). 
SETD2 is highly conserved across various species (Figure 4-2), and its enzymatic activity is 
inhibited by H3K36M and H3G34R/V/W/L mutations (168, 169, 177). Therefore, SETD2 is an 




Figure 4-1. Domain architectures of H3K36 methyltransferases (adapted from (160)). A schematic 
representation of human H3K36 methyltransferases. The SET domain is shown with its pre-AWS and post-
SET domains. C5HCH is a zinc-finger (ZNF) domain, WW domain interacts with Pro-rich peptides, the 





Figure 4-2. Sequence alignment of the SET domains of SETD2 across various species. The secondary 
structure elements in the structure of SETD2 are labeled. Residues that are strictly conserved among the 
five proteins are shown in white with a red background and those that are mostly conserved in red. hs: 
Homo sapiens (human), rr: Rhinopithecus roxellana (golden snub-nosed monkey), pa: Papio Anubis (Olive 
baboon), pc: Puma concolor (cougar), bm: Bos mutus (Domestic yak). This figure was generated from 
ESpript (http://espript.ibcp.fr) (141). 
 
The lysines-to-methionine mutations on other histone lysines also dominantly inhibit the 
methylation of the corresponding lysine residues on wild type histones, which suggests that these 
mutations function through a similar mechanism (167, 168, 178, 179). In fission yeast, 
nucleosomes that contain the H3K9M mutation trap the H3K9 methyltransferase Clr4 at 
heterochromatin nucleation centers to block the enzyme from spreading, which leads to the failure 
of large heterochromatin domain formation (178). This trapping mechanism was supported by the 
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observation that the immunoprecipitation of H3K27M-containing nucleosomes showed an 
increased amount of H3K27 methyltransferase complex PRC2 (169). Interestingly, 
immunoprecipitation of H3K36M-containing nucleosomes also showed higher levels of H3K36 
methyltransferases such as SETD2 and NSD1 (169). However, NSD1 was not inhibited by 
H3K36M in vitro, raising the question of whether the trapping mechanism is also applicable to 
H3K36M (169). 
In vitro H3K9 methyltransferases, such as Clr4 and mammalian G9a, interact with histone 
H3 peptides harboring the K9M mutation in the presence of SAM, the methyl donor for histone 
methyltransferases (178, 180). In addition, the interaction between the H3K27 methyltransferase 
PRC2 and an H3K27M-containing peptide is also dependent on SAM (181). Such interactions 
allow the crystallization of the ternary complex for structural analyses (178, 180, 181). Therefore, 
in order to understand the molecular basis of the regulatory mechanism of the H3K36M mutation 
on the H3K36 methyltransferase SETD2, we determined the crystal structures of the catalytic SET 
domain of mammalian SETD2 in complex with H3K36M peptide and S-adenosylmethionine 
(SAM) or S-Adenosyl-L-homocysteine (SAH) (182). The crystal structures revealed the detailed 
molecular mechanism by which histone mutations affect H3K36 methylation. We and our 
collaborator Songtao Jia at Columbia University also performed biochemical and functional 
studies, which showed that mutations of the histone H3 tail, generated based on the structural 
information, reduced interactions with its H3K36 methyltransferases and the trapping of Set2 by 




4.2 Experimental procedures 
4.2.1 Protein expression and purification 
Human SETD2 (residue 1435-1711) was sub-cloned into a modified pET28-MHL vector. 
The recombinant protein, with an N-terminal hexahistidine tag, was over-expressed in E. coli 
BL21 (DE3) Star cells (Novagen), which were induced with 1 mM IPTG and allowed to grow at 
16 °C for 16–20 h. The soluble protein was purified by nickel-charged immobilized-metal affinity 
chromatography and ion-exchange chromatography. After diluting [NaCl] to 250mM, the purified 
protein was concentrated and stored at –80 °C in a buffer containing 20 mM PIPES (pH 6.5), 250 
mM NaCl, and 10 mM DTT. The His-tag was not removed for crystallization. 
 
4.2.2 Protein crystallization 
Crystals of SETD2-SAM-H3K36M complex and SETD2-SAH-H3K36M complex were 
grown at 20 °C with the sitting-drop vapor diffusion method. The SETD2 protein solution was at 
10 mg/ml concentration, and the protein was incubated with SAM (Sigma) and H3K36M peptide 
(29-APATGGVMKPHRYRP-43) (Eurogentec) at a molar ratio of 1:10:10. The reservoir solution 
contained 0.1 M KSCN and 24% (w/v) PEG 2000 MME. Fully-grown crystals were obtained one 
day after set-up. The crystals were cryoprotected in the reservoir solution supplemented with 10% 
(v/v) glycerol and flash-frozen in liquid nitrogen for data collection at 100K. 
 
4.2.3 Data collection and processing 
X-ray diffraction data set on a SETD2-SAM-H3K36M complex crystal was collected using 
a Saturn944HG CCD mounted on a Rigaku Micromax-003 X-ray generator. X-ray diffraction data 
set on a SETD2-SAH-H3K36M complex crystal was collected at the Advanced Photon Source 
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beamline NE-CAT 24-ID-E using an ADSC Q315r detector. The diffraction images were 
processed and scaled with the HKL-2000 package (144).  
 
4.2.4 Structure determination and refinement 
The structures of the SETD2-SAM-H3K36M complex and the SETD2-SAH-H3K36M 
complex were solved by the molecular replacement method with the program Phaser-MR in 
PHENIX (117). The crystal structure of human SETD2 in complex with SAH (PDB entry code 
4H12) (183) was used as the search model. The phases were used by program PHENIX (118) for 
automatic model building. Manual model rebuilding was carried out with Coot (119). The structure 
refinement was performed with the program PHENIX (118), with translation, libration, and screw-
rotation (TLS) parameters. The data processing and refinement statistics are summarized in Table 
4-1. The Ramachandran plot showed that 100% of the residues are located in the allowed regions 
for both structures. The structures have been deposited in the Protein Data Bank, with accession 
code 5V21 and 5V22.  
 
4.2.5 Thermal shift assay 
The thermal stability of the SET domain of SETD2 with ligands at different concentrations 
was analyzed at various temperatures using the Mx3005P Real-Time PCR system (Stratagene). 
Purified SETD2 protein (5 µM) was titrated with SAM (Sigma) at 0, 0.4, 1 mM concentrations, 
H3K36M (29-43) peptide (Anaspec) at 0, 0.4, 1 mM, and wild-type histone H3 peptide (29-43) 
(Biomatik) as well as its double mutant (H3G34R/K36M, H3K36M/P38V) (Biomatik) at 0 and 1 
mM concentrations. All assays were performed in duplicate for each sample and contained final 
concentrations of 20 mM PIPES (pH 6.5), 400 mM NaCl and 10 mM DTT. Reactions were 
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incubated on ice for 30 min and mixed with the fluorescence dye (SYPRO orange; Invitrogen) for 
monitoring protein unfolding. The temperature was increased from 25 to 99 °C in 1 °C intervals 
over a 75-min period. Fluorescence values for each curve were normalized to the maximum and 
the minimum of the curve. 
 
Table 4-1. Summary of crystallographic information 
 SETD2+SAM+H3K36M SETD2+SAH+H3K36M 
Data collection   
Space group P212121 P212121 
Cell dimensions   
a, b, c (Å) 58.5, 76.3, 77.2 60.3, 77.2, 76.5 
a, b, g (°) 90, 90, 90 90, 90, 90 
Resolution range (Å)1 30-2.42 (2.51-2.42) 40-2.4 (2.49-2.4) 
Measured reflections 71016 77604 
Unique reflections 13529 14491 
Rmerge (%) 10.0 (47.6) 8.5 (42.9) 
I/sI 14.1 (3.2) 18.8 (3.7) 
Completeness (%) 98.1 (96.9) 99.7 (99.9) 
Redundancy 5.2 (5.3) 5.4 (5.3) 
Refinement   
Resolution range (Å) 30-2.42 (2.60-2.42) 40-2.4 (2.58-2.4) 
No. reflections 13077 14082 
Rwork (%) 20.4 (28.3) 19.5 (24.6) 
Rfree (%) 26.9 (35.4) 25.7 (35.2) 
No. atoms   
Protein 1971 1971 
Cofactor 27 26 
Zn 3 3 
Water 36 85 
B-factors   
Protein 35.7 40.9 
Cofactor 25.8 34.6 
Water 29.4 37.3 
RMS deviations   
Bond lengths (Å) 0.016 0.008 
Bond angles (°) 1.4 0.80 
Ramachandran plot residues (%)   
Most favored regions 98.03 95.28 
Additional allowed regions 1.97 4.72 




4.3 Results and discussions 
4.3.1 Construct design and protein expression 
The recombinant SETD2 (residue 1435-1711), which consists of the AWS, SET, and post-
SET regions, was generated based on previous structural studies (183) (Table 4-2).  Since this 
construct showed a high level of expression and solubility from small-scale expression tests in E. 
coli, this recombinant protein was purified from large-scale E. coli culture using Ni-NTA affinity 
chromatography followed by cation-exchange chromatography (Figure 4-3). The two peaks from 
cation-exchange chromatography both correspond to the recombinant SETD2 protein, which was 
pure and homogeneous based on the SDS-PAGE gel and the cation-exchange chromatography 
profile (Figure 4-3). Therefore, fractions corresponding to each peak were pooled individually. 
However, the protein from Peak 1 (fractions #15-20) precipitates after [NaCl] was diluted to 
250mM, while the protein from Peak 2 (fractions #22-30) remained soluble. Therefore, the protein 
from Peak 2 was concentrated to 12 mg/ml for crystallization screens. 
 
Table 4-2. Summary of the construct of human SETD2  
Name Tag Vector Start End Total Residue 
M.W. 











Figure 4-3. Cation-exchange chromatography of human SETD2 (1435-1711). The eluted fractions were 
monitored using absorbance at 280nm and analyzed by SDS-PAGE. P: insoluble fraction of lysate, E: Ni-
NTA eluate, FT: unbound flow through. 
 
4.3.2 Crystal screening and optimization 
The SETD2 protein sample was incubated with SAM (Sigma) and an H3K36M peptide 
(29-APATGGVMKPHRYRP-43) at a molar ratio of 1:10:10. The final protein concentration was 
10 mg/ml. The protein mix was screened for the crystallization condition that was reported for the 
structure of SETD2 in complex with SAH (0.1 M KSCN and 30% (v/v) PEG 2000 MME) (183). 
However, no protein crystal was observed in the condition. Therefore, the protein mix was 
screened for the conditions that consist of varying concentrations of KSCN or PEG 2000 MME, 
and protein crystals appeared after one day in 0.1 M KSCN and 24% (v/v) PEG 2000 MME (Figure 
4-4). After several rounds of optimization, the crystals from this condition diffracted to around 2.4 





Figure 4-4. Crystals of human SETD2 (1435-1711) in complex with H3K36M peptide and SAM. 
Three-dimensional crystals from 0.1 M KSCN and 24% (v/v) PEG 2000 MME. 
 
4.3.3 Structure determination and characterization 
To understand the molecular details of the interactions, the crystal structure of the SET 
domain of SETD2 in complex with the H3K36M peptide and SAM was determined at 2.42 Å 
resolution (Figure 4-5a). In addition, a ternary structure of SETD2-H3K36M-SAH at 2.4 Å 
resolution was obtained from a crystal in the same crystallization condition, and the structure is 
almost identical as the structure of SETD2-H3K36M-SAM (Figure 4-5b). Since SAH was not 
added in the crystallization reaction, it is likely a degradation product of SAM as has been reported 
before (183). For both structures, the atomic models have good agreement with the X-ray 






Figure 4-5. The structure of the SET domain of SETD2 in complex with an H3K36M peptide and 
SAM or SAH. (a) The overall structure of the SET domain in complex with the H3K36M peptide. (b) The 
overall structure of the SET domain in complex with the H3K36M peptide and SAH (in gray) is essentially 
the same as that of the SAM complex. The SET domain is shown in cyan, the H3K36M peptide in green 
stick models and SAM in magenta. Several zinc ions bound to the protein are shown as pink spheres.  
 
Clear electron density of the entire H3K36M peptide (29-APATGGVMKPHRYRP-43) 
and SAM was observed in the SETD2-H3K36M-SAM structure (Figure 4-6). Residues 32-43 of 
the peptide assume an extended conformation, and residues 33-35 form anti-parallel b interaction 
with a strand (residues 1668-1670) in the post-SET motif of SETD2. The last two residues 
(residues 42-43) of the peptide are projected away from the rest of SETD2. The conformation of 
Pro43 is likely stabilized through van der Waals interactions with the side chain of Tyr41 (Figure 





Figure 4-6. Omit Fo−Fc electron density of SAM and H3K36M peptide at 2.42 Å resolution, 
contoured at 3σ. (a) Omit Fo−Fc electron density of SAM. (b) Omit Fo−Fc electron density of the 
H3K36M peptide. 
 
Compared to the structure of SETD2-SAH without a histone peptide (183), the overall 
structures of the AWS motif and the SET domain of SETD2 are almost identical (Figure 4-7). 
However, extensive conformational changes were observed for the post-SET motif of SETD2 upon 
H3K36M peptide binding, with residues 1667-1675 adopting drastically different conformations 
in the two structures (Figure 4-7). Especially, residues 1669-1673 in the SETD2-SAH complex 
directly overlap with residues 33-36 of the H3K36M peptide, and the Arg1670 side chain of 
SETD2-SAH is located in the binding site for K36M of the peptide (Figure 4-8a) (183). Compared 
to the structure of SETD2 in complex with the inhibitor N-propyl sinefungin (Pr-SNF) (183), the 
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conformation of residues 1667-1675 is more similar to that in the SETD2-H3K36M-SAM 
structure, although residues 1669-1673 would still clash with the H3K36M peptide (Figure 4-8b). 
In addition, residues at the C-terminus (1692-1703) of SETD2, which are disordered in the 
SETD2-SAH structure, can be observed clearly and residues 1690-1691 have different 
conformations in the two structures (Figure 4-8a). 
 
 
Figure 4-7. Extensive conformational changes in SETD2 SET domain upon H3K36M peptide and 
SAM binding. Overlay of the structure of SETD2 SET domain (cyan) in complex with H3K36M peptide 
(green) and SAM (magenta) with that of the SET domain in complex with SAH (gray) (183). Red 
arrowheads point to regions of large conformational differences between the two structures, in the post-






Figure 4-8. Large conformational changes of SETD2 upon peptide binding. (a) The binding site for the 
substrate peptide (green) is occupied by a loop of the protein in the free SET domain structure (gray) (183) 
due to large conformational changes for residues 1667–1675 and those at the C-terminus of the SET domain. 
(b) Overlay of the structure of SETD2 SET domain (cyan) in complex with H3K36M peptide (green) and 
SAM (magenta) with that of the SET domain in complex with the inhibitor N-propyl sinefungin (Pr-SNF) 
(gray) (183). There are still large conformational differences, although the steric clash between the 
H3K36M peptide and the post-SET motif is not as severe. The propyl group of Pr-SNF is labeled Pr.  
 
4.3.4 Interactions of H3K36M with SETD2 
Previous studies have reported that H3K36M-containing nucleosomes or peptides pull 
down SETD2 from nuclear extracts more efficiently than their wild type counterpart (169). The 
K36M residue of histone H3 is situated in the active site of SETD2, confirmed by the fact that the 
di-methylated lysine 9 of histone H3 (Mly9) is bound at a similar position in the SET domain of 
its methyltransferase GLP-1 (Figure 4-9) (183). Compared to the di-methylated lysine, the 
methionine side chain does not extend as deeply into the binding pocket, and it is surrounded by a 
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collection of aromatic side chains (Tyr1579, Tyr1605, Phe1650, Phe1664, Tyr1666, Phe1668) as 
well as Met1607 from SETD2. The methyl group of K36M is pointed toward the side chain of 
Tyr1579, away from the direction of the substrate lysine. The binding mode for methionine is 
similar to that of the recently solved structures of G9a-K9M-SAH and PRC2-K27M-SAH (178, 
180, 181), where the same residues that interact with the substrate lysine also interact with the 
mutated methionine residue.  
The methyl group of the cofactor SAM is expected to clash with the methylated lysine side 
chain of the substrate, consistent with the reaction mechanism whereby the methyl group of SAM 
is transferred to the lysine (Figure 4-9). This methyl group is pointed toward the K36M side chain 
of the peptide, but at a distance of 4.2 Å to its sulfur atom (Figure 4-9), which suggests that it does 
not interact directly with the methionine side chain. In fact, the electron density around the methyl 
group is weaker compared to the rest of SAM, suggesting that a mixture of SAM and SAH are 
present in the structure. In addition, the structures obtained with SAM and SAH are essentially 
identical (Figure 4-5b). Therefore, the contribution of SAM and SAH to the interaction between 
SETD2 and H3K36M could be interchangeable, which possibly is solely to stabilize the proper 





Figure 4-9. Detailed interactions between the SETD2 SET domain (cyan) and the H3K36M peptide 
(green) near K36M. The distance between the methyl group of SAM and the sulfur atom of K36M is 
indicated by the dashed line. The bound position of di-methylated H3K9 (labeled Mly9) peptide to GLP1 
(184) is also shown (gray).  
 
Thermal shift assays demonstrated that the addition of SAM alone stabilized SETD2 with 
a small shift in Tm, but the addition of an H3K36M peptide alone had relatively minor effects 
(Figure 4-10a, b). Interestingly, the simultaneous addition of SAM and the H3K36M peptide 





Figure 4-10. Thermal shift assay with the recombinant SET domain of SETD2. Thermal shift assay to 
characterize the interaction between the SET domain of SETD2, SAM, and an H3K36M peptide. (a) 5 µM 
of SETD2 and different concentrations of SAM. (b) 5 µM of SETD2 and different concentrations of 
H3K36M peptide. (c) 5 µM of SETD2 with or without 1 mM of H3K36M peptide in the presence of 0.4 
mM of SAM. (d) 5 µM of SETD2 with 1 mM of four different histone peptides in the presence of 0.4 mM 
of SAM.  
 
Previous studies on the interaction between H3K9M and its methyltransferases, such as 
Clr4 and G9a, demonstrate that the interactions are critically dependent on the cofactor SAM, 
whereas SAH has relatively little effects (178, 180). Therefore, it is interesting that the structures 
of SETD2-H3K36M-SAM and SETD2-H3K36M-SAH were both obtained from the same 
crystallization condition (Figure 4-5b) (169). However, how the methyl group enhances the 
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interaction between G9a and H3K9M is unknown, as the structure revealed that SAM is not 
directly involved in interaction with the methionine side chain either (178, 180). It is possible that 
H3K9M and H3K36M function through different mechanisms in methyltransferase inhibition, 
which could have functional consequences.  
 
4.3.5 Interactions of H3G34 and H3P38 with SETD2 
Besides allowing the H3K36M peptide to bind, another important consequence of the 
structural changes of SETD2 is that residues Gly33-Gly34 of the peptide are completely buried in 
the complex (Figure 4-11). Located in a tight tunnel, there is essentially no space to accommodate 
larger side chains, such as those of oncogenic histone mutations at H3G34 (Val, Leu, Arg, and Trp) 
(Figure 4-11b). In addition, Gly34 of the peptide is flanked by Phe1668 on one side and Tyr1671 
on the other (Figure 4-11a) and mutations of these two residues into alanine completely abolished 
the enzymatic activity of SETD2 in vitro (183).  
 
 
Figure 4-11. Gly34 is located in a tight tunnel that excludes large side chains. (a) Detailed interactions 
between Gly34 and the SET domain. The green arrow points to the direction of any side chain at this residue, 
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which would clash with residues 1668–1669 of the SET domain. (b) Molecular surface of the SETD2 SET 
domain near Gly34, showing that the residue is located in a tight tunnel and is completely shielded from 
the solvent.  
 
Proline isomerase Frp4 regulates H3K36 methylation by Set2 through isomerization of 
Pro38 of histone 3 between trans and cis configurations in fission yeast (170). In the SETD2-
H3K36M-SAM structure, H3P38 is bound in the trans configuration (Figure 4-12), causing a ~90° 
twist in the backbone of the peptide. This allows residues C-terminal to H3P38 to make extensive 
contacts with SETD2. In contrast, a cis configuration of Pro38 is incompatible with the binding of 
the peptide to SETD2, as it will cause severe steric clashes between SETD2 and the peptide. 
Therefore, H3P38 isomerization contributes directly to stable binding by SETD2. 
 
 
Figure 4-12. Pro38 assumes a trans configuration and has favorable interactions with the SET domain. 
The trans configuration of Pro38 of the H3K36M peptide(green) allows residues C-terminal to Pro38 to 
make extensive contacts with SETD2 (cyan).  
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4.3.6 Biochemical and functional studies of H3G34 and H3P38 mutations 
In order to test whether H3G34 or H3P38 is required for the interaction between SETD2 
and the histone H3 tail, G34R or P38V mutation, which abolishes H3K36me3 in cis in budding 
yeast (170), was generated in the context of the H3K36M peptide, given that there is no detectable 
interaction between SETD2 and the wild type H3 peptide. Thermal shift assay indicated that the 
double-mutant peptides H3G34R/K36M and H3K36M/P38V could not stabilize SETD2 (Figure 
4-10d). Therefore, the G34R or P38V mutation could abolish the interaction between H3K36M 
and SETD2. 
To further test this hypothesis, the effects of mutating H3G34 in vivo were examined by 
our collaborator. Since there are multiple histone H3K36 methyltransferases in mammals, which 
might not recognize H3K36 in the same fashion, mutational analyses in fission yeast, which 
contains only a single H3K36 methyltransferase, Set2, were performed (183). Set2 is highly 
conserved with human SETD2, and the key residues for the interactions with H3G34 and H3K36M 
are also highly conserved (Figure 4-13). Fission yeast contains three histone H3 genes, hht1+, 
hht2+, and hht3+, with identical protein sequences (183). Therefore, a Flag-tagged version of H3 
at the endogenous hht3+ chromosomal locus (hht3-Flag) was generated, which expresses as an H3 
of a higher molecular weight that can be differentiated from the other two endogenous H3 (hht1+ 
and hht2+). Western blot analyses showed that both forms of H3 contain H3K36me3, which were 
absent in set2∆ (Figure 4-14a). However, hht3-K36M dominantly blocked H3K36me3 at 
endogenous H3, while hht3-K36R only affected H3K36me3 on the mutant H3 (Figure 4-14a), 
consistent with observations in mammalian systems (166-169). Moreover, H3G34 mutations were 
generated at the endogenous hht3 locus, including the oncogenic Arg, Val, Leu, and Trp mutations 
or mutations to other amino acids with one or two carbon side chains (Ala, Cys, Ser, Asp, Asn, 
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and Thr). All of these mutations severely affected H3K36me3 on the mutated histone H3 in cis, 
but had little effects on H3K36me3 on endogenous H3 (Figure 4-14a).  
Given that H3G34 is very close to H3K36, it is possible that the loss of H3K36me3 on the 
mutated histones is due to effects on antibody recognition due to the mutation on G34. To rule out 
this possibility, in vitro histone methyltransferase assays were performed using affinity purified 
recombinant SET domain of SETD2 and heterotypic nucleosomes from fission yeast strains that 
contain both Flag-tagged mutant H3 and wild type endogenous H3. The incorporation of 
radioactively labeled methyl group was examined by fluorography. The Flag-tagged wild type H3 
is methylated as efficiently as the endogenous H3 by SETD2, whereas Flag-tagged H3 containing 
mutations at H3G34 all showed severely reduced methylation (Figure 4-14b). Therefore, the G34 
position has little tolerance for mutations, which might explain why H3G34 is a hotspot for 
oncogenic histone mutations. 
The requirement of residues for restricting the G34 recognition channel was also tested by 
mutating Tyr301 of Set2, which correspond to Tyr1671 of SETD2. Consistent with our hypothesis, 
the Y301L mutation mildly affected H3K36me3, while a Y301A mutation reduced H3K36me3 
levels even further (Figure 4-14c). 
Moreover, the effects of G34R or P38V mutation on the ability of H3K36M peptide to 
inhibit SETD2 enzymatic activity in vitro were examined by methyltransferase assays. Consistent 
with previous findings, the H3K36M peptide inhibited the activity of SETD2 on recombinant 
human nucleosomes (Figure 4-14d). In contrast, the double-mutant peptides H3K36M/P38V and 
H3K36M/G34R only had minor effects on SETD2 activity in vitro (Figure 4-14d). Therefore, the 





Figure 4-13. Sequence alignment of H3K36 methyltransferases in fission yeast (sp) and human (hs). 
Residues that are strictly conserved among the five proteins are shown in white with a red background, and 
those that are mostly conserved in red. Amino acids that mediates interaction with H3K36M are indicated 
by red asterisks, and amino acids that restrict the H3G34 access channel are indicated by blue arrows. This 





Figure 4-14. In vitro studies of H3G34 and H3P38 mutations. (a) Western blot analyses of H3K36me3 
and Flag-tagged H3 levels. The mutant histone H3s contain a Flag tag, resulting in slower mobility. (b) In 
vitro histone methyltransferase assay with recombinant SETD2 and heterotypic nucleosomes containing 
H3G34 mutations. (c) Western blot analyses of H3K36me3, H3, and Set2-myc levels. (d) In vitro histone 
methyltransferase assay with the recombinant SET domain of SETD2 and histone H3 tail peptides. The 
incorporation of a radioactively labeled methyl group was quantified by scintillation counting. The activity 
without peptide was set to one. Error bars represent the standard deviation of two replicates.  
 
To further examine the effects of H3G34R and H3P38V on H3K36me3 inhibition by 
H3K36M in vivo, K36M/P38V or G34R/K36M mutation was introduced into the endogenous hht3 
locus in fission yeast. Confirmed by western blot, these mutants were efficiently incorporated into 
chromatin (Figure 4-15a). Co-immunoprecipitation analysis of cells expressing Set2-myc and 
Hht3-K36M-Flag showed that Set2-myc interacted strongly with H3K36M containing 
nucleosomes compared to wild type nucleosomes, consistent with findings in mammalian cells 
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(169, 177). However, the interaction was reduced in Hht3-K36M/P38V or Hht3-G34R/K36M 
expressing cells (Figure 4-15b). In addition, ChIP analysis showed that the localization of Set2 to 
one of its target genes tef3 was increased in hht3-K36M cells, but reduced in hht3-G34R/K36M or 
hht3-K36M/P38V cells (Figure 4-15c). Consistent with the idea that the trapping of H3K36 
methyltransferase is responsible for the dominant effects of H3K36M, H3K36 methyltransferase 
Set2 was no longer trapped in hht3-G34R/K36M and hht3-K36M/P38V cells and H3K36me3 levels 
on wild type histones were significantly restored (Figure 4-15d). 
 
 
Figure 4-15. In vivo effects of G34R and P38V on the inhibition of H3K36me3 by H3K36M. (a) 
Chromatin fraction analyses to measure the incorporation of mutant histones into chromatin. Cell lysates 
(whole cell extract, WCE) were separated into soluble and chromatin-bound fractions. Western blot 
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analyses were performed to measure Tubulin (cytoplasmic marker) or mutant histone levels in different 
fractions. (b) Co-immunoprecipitation analysis to examine the interaction between Set2-myc and histones 
containing different mutations. Only one of the three copies of histones was Flag-tagged and contains 
mutations. (c) ChIP analyses of Set2-Flag levels at a target gene tef3, normalized to the silent mating-type 
locus. The mutant histone is GFP-tagged. Error bars represent the standard deviation of three replicates. (d) 
Western blot analyses of H3K36me3 and Flag levels. Only one of the three copies of histones was Flag-
tagged and contained mutations.  
 
4.3.7 Structural studies of H3K36 methyltransferases NSD1 
It is still unclear why SETD2 and NSD2 are inhibited by H3K36M, but NSD1 and ASHL1 
are not (169). Comparison of the sequences of H3K36 methyltransferases shows that residues 
mediating interactions with H3K36M are highly conserved (Figure 4-13). Therefore, the structure 
of NSD1 in complex with H3K36M would shed light on the detailed interaction and functional 
mechanism of H3K36M. 
Based on previous structural studies (174), a construct of human NSD1 (1853-2082) 
containing the AWS, SET, and post-SET regions was sub-cloned into a pET28a vector (Table 4-
3). The protein was expressed and purified with the same protocol as SETD2, except the His-tag 
was cleaved with thrombin overnight at 4 °C after nickel-charged immobilized-metal affinity 
chromatography, and the resulting untagged NSD1 was further purified using cation-exchange 
chromatography, which was pure and homogeneous based on the SDS-PAGE gel and the cation-
exchange chromatography profile (Figure 4-16). After fraction #14-19 was pooled, the [NaCl] was 




Table 4-3. Summary of the construct of human NSD1 
Name Tag Vector Start End Total Residue 
M.W. 
(Dalton) pI A280 Induction Solubility 
NSD1 N-His pET28a 1853 2082 230 26,401 8.1 0.87 3 2 
 
 
Figure 4-16. Cation-exchange chromatography of human NSD1 (1853-2082). The eluted fractions were 
monitored using absorbance at 280nm and analyzed by SDS-PAGE. E: thrombin-treated Ni-NTA eluate, 
pooled: pooled fractions #14-19. 
 
The NSD1 protein solution was incubated with SAM (Sigma) and an H3K36M peptide 
(29-APATGGVMKPHRYRP-43) at a molar ratio of 1:10:10. The final protein concentration was 
20 mg/ml. The protein mix was screened for the crystallization condition that was reported for the 
structure of NSD1-SAM (0.2M Lithium Sulfate, 0.1M HEPES, and 25% (v/v) PEG 3350) (176) 
and four other commercial crystallization screen suites by sitting drop vapor diffusion at 20 °C. 
Crystals were observed from four conditions, including that for the NSD1-SAM structure (Figure 
4-17a). In addition, rod-shaped crystals appeared after one day in three other conditions, such as 
0.2M Lithium Sulfate, 0.1M Tris-HCl pH 8.5, and 30% (v/v) PEG 4000 (Figure 4-17b). After 
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several rounds of optimization of all four conditions, the crystals from these conditions all 
diffracted to around 4 Å using an in-house X-ray source. 
 
 
Figure 4-17. Crystals of mixture of human NSD1 (1853-2082), H3K36M peptide and SAM from two 
conditions. (a) Plate-shaped crystals from 0.2M Lithium Sulfate, 0.1M HEPES, and 25% (v/v) PEG 3350. 
(b) 0.2M Lithium Sulfate, 0.1M Tris-HCl pH 8.5, and 30% (v/v) PEG 4000. 
 
However, after collecting X-ray diffraction datasets from these crystals at the APS 
beamline, the structures solved contained only NSD1 and SAM without the density of the 
H3K36M peptide. Optimizing the crystallization process, such as varying peptide concentration, 
incubation time, and incubation temperature, did not yield any crystals of the complex of NSD1 




4.4 Conclusions and future directions 
The crystal structures of a histone H3K36 methyltransferase SETD2 in complex with a 
histone H3K36M peptide and SAM or SAH were determined, which provide the molecular basis 
of histone substrate recognition by H3K36 methyltransferases. In addition, the structural and 
functional data reveal the functional mechanism of the oncogenic mutations at H3G34 and their 
effects on H3K36 methylation. It also provides the molecular details of Pro38 isomerization in 
regulating H3K36me.  
The SETD2-H3K36M-SAM structure showed that the methyl group of SAM has a lower 
electron density, possibly due to the degradation of SAM during crystallization. Such 
heterogeneity suggested that the methyl group does not contribute to the interaction. Therefore, 
the function of SAM or SAH is to stabilize the proper folding of the catalytic domain of SETD2.  
H3K9 methyltransferases G9a and Clr4 and the H3K27 methyltransferase PRC2 are all 
inhibited by the lysine-to-methionine mutation through increased association of mutant histones 
with their corresponding histone methyltransferases, which reduces the turnover of the 
methyltransferases. H3G34 and H3P38V mutations reduced the interaction between H3K36M and 
H3K36 methyltransferases and alleviate the effects of H3K36M both in vitro and in vivo. Therefore, 
consistent with H3K9M and H3K27M, H3K36M also functions through trapping of SETD2/Set2.  
Interestingly, some H3K36 histone methyltransferases, such as NSD1 and ASHL1 which 
show increased association with H3K36M containing nucleosomes, are not inhibited by the 
H3K36M mutation, therefore raising the possibility that mechanisms other than increased 
association are responsible for the inhibitory effects of H3K36M. As a result, further structural 
studies of the complex of NSD1 and H3K36M could provide valuable information on the 
interaction and functional mechanism of H3K36M with NSD1, which could also shed light on the 
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